List of Biotech, Pharmaceutical & Life Sciences companies in United Kingdom - 524

199 Biotechnologies is an early-stage
company developing first-in-class therapies that target the fundamental mechanisms of aging, with the goal of transforming the landscape of age-related disease treatment and prevention.

4basebio is enabling next generation cell and gene therapies and vaccines with its technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.

The market for polymeric biomaterials is growing quickly, but despite this growth, it is widely recognised in the industry that the ‘holy grail’ solution has not yet been developed. The ideal biomaterial for use in regenerative medicine must: be biocompatible; promote tissue regeneration; have non-toxic biodegradation, have mechanical properties suited to the host tissue and good handling properties in a clinical environment. Our people have developed a patented range of novel polymeric 3-D printing resin-inks that promise, uniquely, to meet all of the above requirements and offer important advantages over the next best alternatives. The polymers and their degradation products are non-toxic and their properties can be tuned to suit a wide range of tissue regeneration applications. These 3-D printable resin-inks will enable medical implants to be fitted to the exact shape and dimensional requirements of each patient, optimising outcomes in applications such as cancer treatment, degenerative spinal conditions and reconstructive surgery. Initial in-vitro and in-vivo testing has provided strong evidence of the anticipated biocompatibility and tissue regeneration properties that will enable multiple stakeholders in the health sector to benefit from improved treatment options for a range of life-changing conditions, not least the patients themselves.

At Abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That's why we're constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health. Abcam is proud to be part of Danaher. Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow's science and technology to improve human health.

We are lateral flow CDMO experts based in the UK supporting global customers bring their assays to market, from proof of concept, through optimisation and scale up to routine manufacture, along with full-service regulatory consultancy support. Get in touch: email info@abingdonhealth.com today. We believe that by developing the high quality, effective lateral flow rapid tests combined with our manufacturing experience and scale, we can provide the means to accelerate access to rapid testing. This means faster diagnosis and screening in the field, accelerating the ability of decision makers to deploy a more rapid response to results. We are committed and honest in all that we do. We value the quality and contribution of all, priding ourselves on building long-lasting and trusting partnerships – because by working transparently with customers, partners and colleagues, we are better together. With an exceptional pedigree in developing and manufacturing rapid tests Abingdon Health are expert in responding to our customers varied needs with specific and customisable solutions. Our mission: To improve life by making rapid results accessible to all. By providing the best lateral flow rapid test solutions, we believe we can support the increase in access to diagnostics across many industries and locations throughout the world. Faster access to results allows for rapid decision making and solutions. This ability has a significant role to play in improving life in so many ways.

Our mission at Abselion is to simplify protein quantification for the scientists making crucial decisions to accelerate the development of biotherapeutics. Our tools help researchers to develop the medicine of the future and to find the best ways to produce new biomolecules. We focus on convenient tools with high degree of automation and low hands-on time to accelerate access to actionable data. Our award-winning Amperia system, built on proprietary Redox Electrochemical Detection (RED) technology, brings a new approach to biologics and viral-vector quantification for confident and cost-effective automated, at-line titre measurement, at any bench or bioreactor. By enabling agile and straightforward access to titre data, we empower scientists to focus on the decisions that can drive bioprocess optimisation and innovation. We are a dynamic, interdisciplinary team working at the intersection of biology, nanotechnology and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion.

Absolute Antibody Ltd is a UK-based biotechnology company founded in Oxford in August 2012. It specializes in recombinant antibody technology and operates from an ISO 9001:2015 certified facility in Redcar, England. The company focuses on improving antibody reproducibility through genetically defined production methods. The core services include recombinant antibody production using mammalian HEK and CHO cell lines, allowing for animal-free and serum-free manufacturing. They also offer custom engineering, providing antibody sequencing and reformatting into over 180 formats, as well as bespoke projects for pharmaceutical, diagnostic, and academic clients. Their product range features over 21,000 defined recombinant antibodies, ensuring consistency across batches, and includes specialized formats for various applications. Absolute Antibody serves a diverse clientele, including 14 of the top 15 pharmaceutical companies by R&D expenditure, biotechnology firms, and academic institutions. The company emphasizes collaboration in therapeutic antibody development and assay standardization.

Accession Therapeutics Limited is based in Oxford, UK. Its platform technology, TROCEPT, is delivering a proprietary internal pipeline for Accession Therapeutics with significant innovation opportunities available for partnering. Products from the platform are expected to have strong clinical and commercial potential, convenient intravenous administration for better patient access and compliance, and a competitive cost of goods sold via an established manufacturing route. The potential of TROCEPT is illustrated in the animation here. Accession Therapeutics has raised >$66m to date backed by high net worth individuals, iGlobe Partners, Primavera Venture Partners, Birk Venture and other international biotech investors.

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Activatec develops technologies to produce biobased ingredients from renewable sources. We are specialised in the evaluation, scale-up and commercialisation of processes to produce biotechnological and plant-based ingredients and materials from currently unused and low-value organic sources. Activatec is a B2B Partner that provides support to the industrial biotechnology sector in the form of research services on a contract basis. We are currently working within a number of international partner projects to design, develop and scale-up novel technologies for the production of emerging and high-value bio-based products.

Partner of choice in specialty, hospital, and rare disease medicines ADVANZ PHARMA is a global pharmaceutical company with the purpose to improve patients' lives by providing the specialty, hospital, and rare disease medicines they depend on. Our ambition is to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with innovative biopharma and pharmaceutical development companies to bring medicines to patients. Headquartered in London, UK, we have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia. Our Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialisation partner network complement our global operations. ADVANZ PHARMA's product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products and pipeline cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, CNS, and, more broadly, rare diseases. We can only achieve our ambition with the passion of our dedicated and highly qualified people, acting in line with our company values of entrepreneurship, speed, and integrity.

Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA. We are a highly experienced team with a long-standing track record of entrepreneurial and investment success through turning break-through science into approved medicines or medical products. We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach. Our investments are focussed in new drug discovery - small molecules, biologics and new modalities - med tech, enabling technologies and vaccines. As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well connected team to support each investment. We work in close alignment with our management teams, and partner with them to realise their vision - achieving superior financial returns by bringing innovation to patients. The companies in which we have invested since the year 2000 have discovered and developed, fourteen approved medicines and products - to the benefit of patients, physicians and our investors.

Aelius Biotech is a UK-based biotechnology company founded in 2018, located in Newcastle upon Tyne. The company specializes in developing in vitro gastrointestinal models, which simulate the digestive process. This innovative model includes cell-compatible mucus, allowing for a comprehensive understanding of digestion and absorption. Aelius Biotech offers contract research services focused on animal-free testing for pharmaceuticals, consumer health products, and functional foods. They have collaborated with notable clients, including Huel, and have attracted interest from the alternative protein and lab-grown meat sectors. The company has experienced significant growth, expanding its workforce and revenue following successful funding rounds in 2023 and 2025.

Who are we? We are AF ChemPharm, established in Sheffield, England, in 1998. We are a chemistry-based contract research organisation, and are specialists in driving discovery by simplifying synthesis. We provide a straightforward, cost-effective and convenient route for bringing expertise in chemical synthesis into your projects. Whatever your core focus, AF ChemPharm is on hand to help you streamline your workflow if you require chemical synthesis. Though we are principally involved in the drug discovery and pharmaceutical sectors, we are a reactive and versatile company, and have current and previous clients from a diverse range of industries. We've worked with biomedical academic research groups, functionalised polymer manufacturers, fine chemical suppliers and emerging-technology firms, amongst many others. What do we offer? Our clients expect high quality, reliable and cost-effective consultancy, custom synthesis and contract research, and we are proud to say that we can deliver on these expectations. We are situated in purpose-designed, state-of-the-art laboratories in central Sheffield, equipped with kilo-lab facilities, and we use a world-class analytical suite for the characterisation of your projects. We work with multi-national companies, universities, SME's and brand new start-ups; whatever the size and direction of your company, we pledge the same commitment to excellence in science, communication and customer service . Our team are all PhD chemists, with backgrounds in synthetic organic and organometallic chemistry from both academia and industry, and we have recently appointed two external scientific advisors of the highest calibre - Prof. Joe Harrity of Sheffield University and Prof. Alan Spivey of Imperial College, London.

AgeCurve Limited is a company that offers tools to measure scalable single cell somatic mutation burden across the life sciences market space. They also provide a deep age profiling kit intended to calculate comprehensive biological aging patterns in a saliva sample.

Akamis is a clinical-stage oncology company whose mission is to leverage its groundbreaking T-SIGn® platform to positively impact the lives of people living with cancer. We are developing a portfolio of solid tumor-targeted T-SIGn® therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. Akamis’ growing pipeline of T-SIGn® therapeutics is anchored by its lead clinical-stage program, NG-350A, which is being investigated in an ongoing Phase 1 clinical study in patients with metastatic or advanced epithelial tumors. Akamis has a number of T-SIGn® platform-focused collaborations with leaders in the immuno-oncology field including BMS, Merck, and the Parker Institute for Cancer Immunotherapy (PICI)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

AKL Therapeutics is a pharmaceutical company changing the way drugs are developed by seeking inspiration from nature to combat some of the biggest challenges facing modern medicine today. We are committed to transforming patient’s lives through pioneering innovation. We begin by identifying secondary metabolites of plant origin, with proven efficacy and safety. These metabolites are then synthesized before undergoing standard pharmaceutical clinical development. This innovative approach greatly increases the chances of success, while reducing the risk of side effects. Formal human clinical trials are currently underway assessing the safety and efficacy of an investigational oral therapy, ‘APPA’ in the treatment of osteoarthritis, a common and devastating disease with limited treatment options and no cure. APPA is also being evaluated in other inflammatory diseases and other molecules are also under investigation. AKL Research & Development Ltd, trading as AKL Therapeutics Ltd, welcomes enquiries from potential investors and partners as we continue the development and commercialisation process.

Alacrita is a pharma and biotech consulting firm whose value to clients is founded on the first-hand experience of its subject-matter experts. Consultants who have spent their careers discovering, developing, manufacturing and commercializing drug products. Our core team leverages a purpose-built network of over 250 such experts who are brought into project teams when specialist expertise is needed. This allows us to provide clients with precisely relevant support on a range of R&D and business issues. We do this while also offering the speed and flexibility expected from a professional life science consulting firm. Our expert teams are ready to support you through every step of the pharmaceutical product development process, leveraging our scientific, clinical and commercial expertise to help you maximize value at each stage. We offer substantial expertise & experience in the following areas: Product Development Services: - Clinical Development - CMC & Supply Chain - Interim Chief Medical Officer Support - Preclinical Strategy & Execution - Regulatory Affairs - Research & IP Evaluation Strategy & Commercialization Services: - Business Plans & Fundraising Support - Opportunity Mapping - New Product Planning - Launch Planning Business Development Services: - Asset Scouting - Due Diligence - Licensing, Partnering & Dealmaking - Pharma & Biotech Valuations Visit www.alacrita.com to learn more.

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Alesi Surgical announced in 2023 that it had attained FDA clearance for its groundbreaking Ultravision2 smoke management solution. The breakthrough new Ultravision system includes the world's first surgical tool integrating electrosurgery and class-leading surgical smoke control in a single laparoscopic device. Alesi Surgical was founded to develop and commercialise products that improve the safety, efficacy, and outcomes of surgical procedures. The company is a spin-out of the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre in the UK. Alesi Surgical has a unique level of access to experienced surgeons, surgical trainers, and trainees, which allows it to identify issues in procedures and design devices to address these issues. The company is active in the research and development of novel surgical technologies. It has a ‘needs-driven' pipeline and product development is informed by robust testing by surgical trainers who advise on the utility, usability, and integration of products into surgical practice. Ultravision is designed to deliver rapid and continuous resolution of surgical smoke. It is a small, stand-alone, portable unit fully compatible with current laparoscopic equipment and electrosurgical instruments. Alesi Surgical welcomes approaches from research-based companies or inventors who are interested in exploring potential synergies.

Allergy Therapeutics is a visionary immunology business with specialist experience in the research and development of allergy treatments. We have a well-established commercial presence in Europe and are focused on the US market. We specialise in the diagnosis and treatment of allergy. We mainly sell our products in European countries and our pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, as well as a peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside of allergy are also under evaluation.

At Alliance Pharma plc (AIM: APH) we are a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world. We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. We have previously enhanced our organic growth through selective, complementary acquisitions. Headquartered in Chippenham, UK, we employ around 290 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. Over the last year, Alliance has sharpened its purpose, vision and strategy to align with the stated move towards a predominantly consumer healthcare company, to better position the company for the future, and in response to changing underlying market dynamics. In line with this new strategy, Alliance will focus on the global priority categories of helping damaged skin and supporting healthy aging. Our vision is to be a high performing consumer healthcare company, built on a portfolio of leading, trusted and proven brands. Consumer health products currently deliver 75% of our revenue sales and this continues to be an area of focus going forward. For more information, please visit our website: www.alliancepharmaceuticals.com Adverse Event Reporting Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Pharmacovigilance at Alliance Pharmaceuticals (tel: 01249 466966, email: pharmacovigilance@alliancepharma.co.uk)

AlveoGene is an innovative company focused on transforming rare respiratory disease outcomes using inhaled gene therapy. AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC). The GTC was founded in 2001 to catalyse the application of pioneering research to gene therapy development and manufacturing related to cystic fibrosis and other respiratory diseases, and originated at Imperial College London and the Universities of Oxford and Edinburgh. AlveoGene has secured an exclusive licence to a proprietary and validated next-generation lentiviral delivery platform developed by the GTC for the treatment of respiratory diseases with high unmet need (excluding the use of the CFTR gene which is mutated in cystic fibrosis). Gene therapies developed using our “InGenuiTy™” platform can be delivered through a nebuliser, transducing lung epithelial cells with high efficiency and producing a long duration of action, and can achieve these effects following repeated administration. The platform has been developed over more than a decade, supported by approximately £72 million in grant funding, including from the Wellcome Trust, Department of Health and Social Care, Medical Research Council and the Cystic Fibrosis Trust.

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally restore normal physiological function in women suffering with mixed urinary incontinence. The company's first therapy, Amber UI, is an intelligent closed-loop bioelectrical therapy for urge and mixed urinary incontinence. The startup has also acquired Bioinduction, a fellow U.K.-based company and the maker of the Picostim DyNeuMo platform.

Formed in late 2017, AMLo Biosciences is dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify patients' true risk of disease progression. Those patients who are genuinely at low-risk of disease spread can be provided reassurance and better-informed follow-up care, while those identified at risk of metastasis are enabled to receive timely treatment. The test under development – AMBLor® – will be simple to use and fits seamlessly into current diagnostic practice. AMLo Biosciences has been founded by a team with an internationally acclaimed research track record in the melanoma field, through identification of translational biomarkers, drug discovery & development and the building of biotech companies.

AMPED PCR Ltd is a biotech startup based in Bethania, North Wales. The company manufactures PCR reagents that outperform industry gold standards while costing a fraction of the price. They provide molecular diagnostics solutions for researchers in Life Sciences and Applied Markets.

At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches, addressing limitations associated with the use of a narrow range of protein degrading mechanisms. Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation. Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

AMPLY Discovery is a Belfast-based techbio company that deploys machine learning and synthetic biology to mine vast biological data to discover novel drug and nutraceutical candidates. Their technology digitizes life's diversity, using next-gen sequencing for drug discovery to tackle complex diseases such as cancer, metabolic disease, and infectious diseases through AI (artificial intelligence). They have raised over €1.6 million in grant funding from Innovate UK to develop their drug discovery platform.

Amytrx Therapeutics is advancing a new class of peptide therapies to overcome inflammatory diseases—with a vision of providing transformative medicines to patients. Drawing on 25 years of research, Amytrx is harnessing the power of novel anti-inflammatory peptide discoveries to advance new medicines aimed at the prevention and treatment of inflammatory diseases. Our lead therapeutic candidate, AMTX-100, is bioengineered from human protein sequences that modulate the immune system by a natural process, reducing pathogenesis in a range of chronic diseases mediated by excessive inflammation. Joining forces with institutions for clinical research, Amytrx Therapeutics is dedicated to transforming the conventional treatment of chronic inflammatory diseases using biological technology that is easily understood by the human body in a way that is safe, effective, and simple to use.

Welcome to Anatomise Biostats. Our biostatistics services are designed to support Biopharma and Medtech/Medical Device SMEs and start-ups in their R&D and clinical trials projects throughout the regulatory approval process and beyond. 💡 Our Mission: We aim to facilitate innovation in the life sciences sector while assuring patient benefit and safety, offering unwavering support throughout your journey. 🌐 Who We Serve: Our services cater exclusively to Biopharma and Medtech/Medical Device SMEs and start-ups, and are fine-tuned to address unique industry challenges as they arise. 📈 Specialized Expertise: Our team of biostatistics and bioinformatics experts ensures data-driven precision in your R&D and clinical trials. 🔍 Navigating Regulatory Waters: We guide you through evolving regulatory requirements with confidence. 🤝 Dedicated Partnership: We're not just consultants; we're committed to the success of your project and longer-term pipeline. 🌟 Results-Focused: Our focus is on delivering accurate insights for informed decision-making. Ready to embark on your life sciences journey? Connect with Anatomise Biostats today, and let's chart a course to success together. #Biostatistics #Bioinformatics #LifeSciences #Medtech #Biopharma #BiometricsConsulting #RegulatoryApproval #ClinicalTrials #FunctionalServiceProvider

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE’s commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE’s GCP-compliant laboratories in the UK and the United States. Services include custom made assay development and clinical trial testing for the pharmaceutical industry. Over 80 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

Antikor is a privately-held biotechnology company originally spun-out from Imperial College. We specialise in the discovery and development of small-format Antibody (Fragment) Drug Conjugates, known as FDCs. FDCs are a form of targeted cytotoxic chemotherapy combining the specificity of antibodies with the potency of small-molecule chemotherapy drugs. Specifically, FDCs are smaller than conventional Antibody Drug Conjugates (ADCs) meaning better tumour penetration and more rapid systemic clearance, potentially leading to a higher clinical therapeutic index. Antikor are developing the next-generation of solid tumour therapies, with a major interest in gastro-intestinal cancers.

Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics.

Anuva is creating the world's most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies, which greatly empower drug development opportunities.

APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility. APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development. APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners. Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. For more information, please visit our website at www.apollotherapeutics.com

APS Biocontrol Ltd. (APS) develops biocontrol solutions for the management of bacterial diseases and other microbial contaminants in agriculture and food processing, where concerns regarding the use of synthetic chemicals have resulted in a programme of withdrawals that will have a dramatic impact on the ability of (a) growers to achieve commercial yields and quality and (b) suppliers to ensure the quality of post-harvest packed produce. APS' patented Biolyse technology (based on naturally-occurring antimicrobials; bacteriophage) provides safe, effective and environmentally-sustainable replacements. If you have a problem with bacterial breakdown or contamination, in any sector, our Biolyse technology could be an effective solution. APS is also the company behind Scotland's favourite insect repellent, Smidge (further details can be found at www.smidgeup.com)

Aptamer Group develops Optimer® binders to enable innovation in the life science industry. Get our newsletter: https://aptamergroup.com/newsletter

Arctoris Ltd is a biotechnology company founded in 2016 and based in Oxford, UK, with additional locations in Singapore, Boston, and Abu Dhabi. It operates as a tech-enabled Partnership Research Organization (PRO) and utilizes its proprietary Ulysses platform, the first fully automated drug discovery platform, to enhance research and development processes for biotech, pharmaceutical, and academic partners. The company employs over 40 experts in various fields, including cellular and molecular biology, biochemistry, and machine learning. Arctoris offers services such as Experiments-as-a-Service, integrated drug discovery, and collaborative R&D, providing end-to-end support from target identification to preclinical candidate development. The Ulysses platform combines robotics and advanced data science to deliver high-quality datasets, reducing human error and accelerating project timelines. Arctoris collaborates with biotech startups, large pharmaceutical companies, and AI-driven drug discovery firms, focusing on oncology, neurology, and other therapeutic areas.

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

At Argent BioPharma, we are committed to pioneering the future of healthcare. Our approach is rooted in a profound understanding that advancing medical science is not just about treating diseases but pre-empting and redefining how they are managed. This philosophy guides our R&D efforts, where we focus on the intricate science of the immune system and the exploration of advanced technologies. As we progress on this ambitious path, we invite you to follow our journey and be a part of a transformative shift in healthcare. At Argent BioPharma, we're not just changing treatments; we're changing lives.

Arrayjet Ltd is accredited to ISO13485 and providesCRO/CMO liquid handling solutions to support a variety of microarray applications. Their high-speed microarray spotters utilize a patented, non-contact, inkjet technologyfor printing multiplex array-based assays onto slides, Point-Of-Care devices, biochips and microplates.COVID-19: Re-purposed its in-house antibody screening technology to create a population-scale diagnostic program that will help scientists better understand the behavior of the COVID-19 virus and further the rapidity of a global vaccination program.

Artios is on a mission to kill cancer by exploiting DNA damage response (DDR) and repair pathways that are leveraged by cancer cells to promote their survival. Our specialized DcoDeR platform integrates Artios’ leadership capabilities, expertise and experience in DNA damage biology and drug discovery to systematically discover and develop medicines targeting the totality of the DDR. We have built an extensive DDR focused pipeline designed to address areas of high unmet needs across solid tumour indications including our ATR inhibitor, ART0380, and our Polθ inhibitor ART6043, as monotherapy and combination treatments. Together with our strategic partnerships with Merck KGaA and Novartis, and research collaborations with premiere institutions like Cancer Research UK, The Institute of Cancer Research, The Netherlands Cancer Institute, and the Crick Institute we are pioneering validated approaches to DDR drug discovery. Visit our website at https://www.artios.com/ for more information. Artios is based at the Babraham Campus in Cambridge, UK. If you are interested in working at Artios and have the qualities to be part of our team, please submit your application via our website. We are also very mindful of scams that involve recruitment. At this time please note we are currently not working with any third parties in India for recruitment.

Ascend is a development partner that supports life-science innovators in bringing gene therapy products to patients. Our team has deep expertise in gene therapy development and commercialization to offer unparalleled collaboration while working to develop your products from the bench through the clinic and beyond. Scientific innovation driven by quality and responsibility are at the core of our business. To set a new standard in the industry, we have invested in a world-class analytical toolkit within our flexible and scalable AAV platform of next-gen technologies, all built to find the perfect balance of yield and quality for each process. Let’s aim higher and develop the next wave of accessible life-saving therapies together!

Astoriom is a globally recognised leader in outsourced stability storage and biorepository solutions, with over 30 years of industry experience. We specialise in providing comprehensive stability storage and validation services to pharmaceutical companies, biotech firms, medical device manufacturers, and other life science organisations worldwide. Our services ensure the highest standards of quality and compliance, making us a trusted partner in the industry. Why Astoriom: - Expert Team: Our highly experienced and trusted professionals ensure the highest quality of service. With decades of expertise, our team is dedicated to maintaining the integrity of your products. - Extensive Capacity: We offer over half a million cubic feet of storage at all ICH conditions, accommodating a wide range of temperatures from liquid nitrogen-cooled -196C to +60C. This vast capacity allows us to meet diverse client needs efficiently. - State-of-the-Art Systems: Our automated inventory system and 24/7 alarming ensure robust security, and continuous monitoring. Our systems are designed to provide real-time updates and immediate alerts to ensure the safety and stability of your products. - On-Site Engineers: Dedicated service and validation engineers are available on-site, providing immediate support and maintenance ensuring the continuous operation of storage systems. Astoriom's Core Services: - Stability Storage - Biorepository - Accelerated Ageing Testing - Disaster Recovery - Photostability - Thermal Cycling - Validation Service - 24/7/365 On-Call Repair At Astoriom, every sample matters because everyone's health matters. We are committed to treating each sample entrusted to us with the utmost care, providing reliable and innovative solutions worldwide to ensure the integrity and safety of your products.

Driven by innovative science and our entrepreneurial culture, we are focused on the delivery of life-changing medicines that are fuelling growth and contributing value to patients and society.

Since 1987, Astrea Bioseparations has been pioneering the design, development and manufacture of affinity purification technology for lab-scale and industrial-scale bioprocessing. With over 25 years experience and success in the development of affinity products and design of new custom adsorbents, Astrea is a world leader in its field. Astrea Bioseparations has sales and support offices in North America and Europe, R&D facilities in Cambridge, UK and manufacturing facilities located on the Isle of Man, British Isles and Joliette, QC, Canada ensuring that we are able to meet your needs and support your application wherever you are. OUR EXPERTISE: • Extensive range of bioseparation products • Custom designed chromatography adsorbents • Over 25 years experience & success • Cost effective solutions • Proven Mimetic Ligand™ technology • Dedicated professional service • Full technical support & in-house training • Experts in adsorbent development & downstream process optimization • Established manufacturing facility (ISO 9001)

Crafting shelf-stable science inspired by hedgehogs, Atelerix is the answer to the cryopreservation headache. With a gel that's not just cool but doesn't need to be cold, they're setting cells, tissues, and viruses free from the icy grip of traditional storage and shipping methods. Welcome to the future of bioscience, where the storage is easy, and the cells are always fresh.

aTen Therapeutics is an innovative biotechnology company developing novel therapeutic antibodies to target a fundamental control pathway associated with cancer and several other major diseases. Their technology is focused on antibody discovery and cutting-edge technology development.

PROVIDING DMPK & CLINICAL PHARMACOLOGY EXPERTISE TO PHARMA, BIOTECH, ACADEMIC & CHARITABLE ORGANISATIONS. Aucuba Sciences Ltd was established in 2016. Specialising in DMPK and Clinical Pharmacology knowledge for drug discovery and development programmes, the company provides advice and expertise to assist in the resolution of drug discovery and development challenges.

Charnwood Discovery is a life sciences company that specializes in research and development services for the biotechnology and pharmaceutical industries.

Aurora specializes in minimally invasive, regenerative technologies. It is our vision to be the leader in advanced spinal technologies which will impact lives worldwide. Based in Carlsbad, California we design, develop and manufacture quality spinal implants to be sold worldwide.

Aurum Biosciences is developing novel therapeutics and diagnostics in areas of unmet clinical need. The initial indication for Aurum's ABL-101 injectable is for the treatment of acute ischemic stroke. The company is focused on developing oxygen carriers for use as therapeutics and diagnostics.

Autifony Therapeutics Limited (“Autifony”) is a clinical stage biotechnology company dedicated to developing new medicines to treat rare genetic CNS disorders by deploying its pioneering ion channel drug discovery platform.

Focused on the development of precisely targeted, controlled and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.

Autoscribe offers a wide portfolio of Laboratory Information Management Systems (LIMS). We develop, implement and support configurable Solutions for customers in the USA, UK and worldwide in a variety of industries, such as: - Pharmaceuticals; Drug Discovery, Development & Manufacture - Healthcare & Medical Research - Biobanking - Veterinary - Petrochemicals - Food & Beverage - Energy & Power Utilities - Minerals & Mining - Building & Construction - Environmental Management - Telecommunications - Consumer Products - Contract Testing Laboratories Available on and off the shelf, our scalable, fully configurable LIMS, help our customers manage their laboratory workflow in a key areas such as, but not limited to: - Individual & Bulk sample Entry / Registration - Sample Reception, Preparation, & Allocation - Creation of Test suites - Test Scheduling - Result entry & Validation - Quality Control - Result Approval & Report Analysis Further benefits which add value to our solutions are: - Dynamic Reporting - Barcoding Capability - Competency Monitoring and Management - Resource Planning - Instrument Calibration and Maintenance - Instrument Data Importing - Complaints & Feedback Management - Regulatory Compliance for Audit - In-built Future Proofing - Concurrent, Perpetual Licences - Ability to link to multiple on or off-site Labs - Proof of Concept available - Localized Support for all International customers Autoscribe also regularly hosts free Seminars and Training Workshops. For more details, visit our official website below:

Our mission is to shape the future of medicine by developing safe and efficacious drugs, and high performing diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms. The Affimer® platform is a novel class of biotherapeutic based on a naturally occurring human protein. It is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families. Avacta’s proprietary pre|CISIONᵀᴹ targeted chemotherapy platform, releases active drug only in the tumour, thereby limiting systemic exposure and improving the overall safety and therapeutic potential of these powerful anti-cancer treatments. Avacta expects to take its first pre|CISIONᵀᴹ drug candidate, AVA6000, a targeted form of the standard-of-care Doxorubicin, into the clinic by the second half of 2021. By combining these two platforms the Company is building a pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta’s diagnostics division, based in Wetherby, UK., utilises it’s proprietary Affimer® platform to develop high performing diagnostics and works with partners world-wide to develop Affimer reagents with the objective of establishing royalty bearing license deals.

At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). With our deep understanding of the brain and our suite of proprietary gene therapy platforms and delivery technologies, we are working relentlessly to overcome the challenges of delivering the right drug to the right place. Our innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases. The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

AVITA Medical (NASDAQ: RCEL, ASX:AVH) is a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient's own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a Biosynthetic Wound Matrix, in the United States.

Axis Shield is a company that specializes in the development and manufacture of in vitro diagnostic tests, focusing on proprietary markers for early diagnosis and management of critical illnesses like cardiovascular and neurodegenerative diseases.

World leaders in iPSC technology supporting the next generation of advanced models for drug discovery We provide biopharma and virtual organizations with human iPSC-derived cells and outsourced laboratory services to support drug discovery in the neurodegenerative, neuroinflammatory, and cardiotoxicity areas. As leaders in human induced pluripotent stem cell (iPSC) products and services, we support the pursuit of more human-relevant in vitro models to develop better, safer therapies. We have over a decade of experience supplying top ten Biopharma institutions and drug discovery companies with robust, high-quality in vitro models and custom lab services. Our industry-leading iPSC capabilities support the pursuit of advanced in vitro disease models and supply volume for organ-on-a-chip devices and microfluidics platforms. From simple monoculture models to complex co- and tri-culture and 3D models, we continue to pioneer the advanced utility of iPSCs for research and drug discovery.

Axovia Therapeutics is dedicated to the research and development of novel AAV gene therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers. Axovia is currently developing therapies for patients with mutations in the BBS1 gene which manifests as Bardet Biedl Syndrome. Our initial goal is to halt the progression of BBS by targeting the most debilitating aspects of the neurological, metabolic and retinal dysfunctions.

Bactobio is a London-based biotechnology company that uses synthetic biology, next-generation sequencing, and machine learning to culture the 99% of microbes which have previously been unculturable. Our exclusive access to nature's greatest bioresource allows us to discover novel chemical and biological products in both healthcare and agriculture. Our first targets are to discover novel antibiotics against the worst bacterial infections and help make plant protection sustainable.

Badrilla is a biological reagents company focused on providing effective, well validated research antibodies to cardiac proteins, chemistry kits for the study of S-palmitoylation and standards for precise and accurate quantification of immunoassay data. Do you need reagents for your research project that are not currently available? We work with researchers to develop new probes in emerging areas of research, bringing them to the whole community after prompt and thorough characterisation. Approach us with your ideas, we'd like to work together.

Barinthus Biotherapeutics plc (formerly Vaccitech plc), a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company’s prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing a COVID-19 vaccine with the University of Oxford, which is approved for use in various territories and licensed worldwide to AstraZeneca through Oxford University Innovation. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.

Basecamp Research is a market leader in mapping biodiversity for AI-based design of biological systems. We match and refine novel proteins for our partners' exact industrial, therapeutic or diagnostic applications using BaseGraph™, a new generation of AI design that is powered by the first-ever high-resolution map of global genetic biodiversity. Understanding the full genetic, evolutionary, and environmental context of each protein allows Basecamp Research to design tailored proteins for specific applications without the need for expensive and time-consuming directed evolution campaigns. We're a team of explorers, scientists and policy experts driven by our ambition to protect and learn from nature's diversity, whilst delivering life-changing breakthroughs to those who need them most.

Baseimmune was founded in 2019 as a discovery phase start-up in the antigen discovery and vaccine development field.

Bastion Therapeutics is a preclinical stage biotechnology company with a mission to develop novel Treg therapies to address the unmet clinical need for inflammatory disorders. We leverage our proprietary GRIT™ platform technology to enhance Tregs to modulate the immune system and overcome challenges associated with previous generations of Treg therapies. Our vision is to provide life-changing therapies that are efficacious, durable and safe to patients suffering from inflammatory disorders.

BBI Solutions - Serving the Science of Diagnostics BBI Solutions is a leading expert in immunoassay development and manufacturing services, and provides an extensive portfolio of products and technologies to the global research and diagnostic markets. The contribution that the BBI Group makes towards achieving this is by adhering to our Mission; ‘To deliver exceptional products and technologies that people rely on to enjoy a better quality of life. Through innovation, partnership, effective delivery and the collaboration of our people, we constantly strive to help set industry standards, engender trust and build our reputation for excellence

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialities, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry. Biocomposites products are now used in over 100,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.

BioCorteX is a biotechnology company that utilizes artificial intelligence and computational modeling to enhance therapeutic development, particularly in the area of microbiome-host interactions. The company operates through two entities: Biocortex Ltd, established in the UK in 2021, and BIOCORTEX, INC., which opened in 2023. BioCorteX specializes in AI-driven platforms that aim to reduce risks in drug development and improve clinical trial outcomes. The company offers several core services, including in silico clinical trials that simulate drug-bacteria-host interactions to predict clinical outcomes, microbiome analysis to assess how bacterial diversity affects drug efficacy, and therapeutic development support for various sectors such as pharmaceuticals and cosmetics. Their proprietary foundational emulator integrates microbiome data with AI to simulate human physiological responses to drugs, while their drug interaction models test numerous medications to identify success factors, particularly in antibody-drug conjugates for cancer therapy. BioCorteX targets pharmaceutical companies, biotech firms, and the cosmetics industry, providing insights to optimize product performance and safety.

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain. The Company’s lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma and diffuse midline glioma. MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.

At Biofortuna we form unique partnerships with the most innovative healthcare and life science companies and work together to enhance health and wellbeing all over the world. Our services are wide-ranging, and whether we are supporting diagnostic companies, food safety experts or life science specialists our objectives are the same; to form long term partnerships and become a valued extension of your team. We do that by solving problems and presenting opportunities. We listen to your requirements, develop customised solutions and deliver them with openness and transparency. Operating from state-of-the art, purpose built premises, and benefiting from ISO 13485 certification, ISO 17025 accreditation and FDA registration, we have a proven track record in the development and large-scale manufacture of PCR and LAMP molecular assays and immunoassays.

We have 24 years of experience doing Process Simulation and Economic Analysis! Our software has 15 years of history now. You may know BioSolve Process, which can let you evaluate the following and beyond: - Process Optimization - Process Simulation - Techno-Economic Assessment - Green Design which can feed into LCA Our users can be: - MSAT - R&D Scientists - Managements to review the data - Tech Transfer - Innovative Supplier - Engineers Back in December 1998, Biopharm Services was founded by Andrew Sinclair to develop technology solutions and services for: - the biopharmaceutical manufacturing business - covering biologic products (inc. viral vectors, mRNA, ADC and more) - and facilities and manufacturing strategy

Bio Products Laboratory Limited (BPL) is headquartered in Elstree, near London (UK). BPL's mission is to provide a continuous supply of high quality plasma derived products to a growing global market, through investing in the latest research, technology and manufacturing methods, and by ensuring on-going and responsive support to health professionals throughout the world. We are committed to research and development to maintain a key position in a constantly changing market in the 21st century. BPL manufactures a wide range of products from blood plasma. These products fall broadly into three main groups: • Human Albumin Solutions • Human Immunoglobulins • Human Coagulation Factors

Biosceptre is developing a multi-targeted universal CAR-T system, designed to incorporate our nfP2X7 technology, to be capable of treating a range of cancers.

Biotherapy Services Ltd. (BTS) is a pharmaceutical biotechnology company developing and delivering novel autologous therapies for complex and chronic wounds 🥽 🥼. Biotherapy Services, composed of clinicians, technicians, and healthcare managers, was created to bring the most effective platelet-enriching technology to medical practices in the UK and Eire 👩‍🔬 👨‍⚕️. The company has developed proprietary expertise and a unique GMP standard operational service model to provide the RAPID™ Biodynamic Haematogel autologous wound care treatment, targeting complex and chronic wounds such as Diabetic Foot Ulcers and Pressure Sores 🦵️ 🦶️. The RAPID™ Gel harnesses the patient’s own platelets to speed healing, growth, repair, and recovery 🧬️. BTS is currently conducting the RAPID-1 Trial to investigate the efficacy of RAPID™ Gel in wound closure compared to usual and customary care 🔎.

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio's trademarks, visit www.bit.bio/trademarks

BiVictriX is an emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer. Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues. Thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of the major factors limiting the development of this otherwise promising therapeutic class. BiVictriX's Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links the Company's in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications. The Company's initial focus is on the generation of Bi-Cygni Antibody Drug Conjugates (ADCs), with future plans to expand the technology to other therapeutic modalities (Cell engagers and CAR-T).

Bloomsbury Genetic Therapies ("Bloomsbury") is a clinical-stage biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies. The Company was spun out of University College London and launched in October 2022 with funding from UCL Technology Fund. Bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs.

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics’ expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

Blue Earth Therapeutics Ltd is a clinical stage radiopharmaceutical company dedicated to the advancement of next generation targeted radiotherapeutics to treat patients who have cancer. With proven leadership and therapeutic radiopharmaceutical expertise, Blue Earth Therapeutics has an emerging pipeline of precision targeted therapeutic radiopharmaceuticals, initially focused on prostate cancer with plans to expand into additional disease areas in oncology. The Blue Earth Therapeutics story begins in 2021, when the company was formed in Oxford, UK as a sister company to Blue Earth Diagnostics Ltd and part of the Bracco family of companies. Bracco Imaging S.p.A. is a world‐leading diagnostic imaging provider, headquartered in Italy. The Blue Earth Therapeutics team strongly believes in the potential of targeted therapeutic radiopharmaceuticals and is committed to bringing these innovative technologies to clinicians and patients worldwide.

Our vision is to provide every baby with a breast milk microbiome, for equal access to a healthy future.

We turn ordinary scans into extraordinary insights because every patient deserves expert-level care, anywhere. Impactful. Scalable. Smart. Brainomix 360 enhances stroke imaging interpretation for neurologists, interventionalists, and radiologists while seamlessly fitting into existing radiology workflows. Delivering the right insights, to the right people, at the right time. Since our 2010 spin-out from the University of Oxford, we've developed award-winning, AI-powered imaging biomarkers and software solutions that empower physicians worldwide to make critical, life-saving decisions in stroke and lung care.

Briefly helps give scientists headspace to design their experiments.  Our experiment builder helps create clear, consistent, visual experimental plans, with a copilot that takes care of the busywork.

Britannia Pharmaceuticals, part of the STADA Arzneimittel AG group of companies, is a UK based pharmaceutical company specialising in the neurology market. Britannia focuses on innovative products for chronic and serious medical conditions, and in particular, the treatment of Parkinson’s disease. We are highly committed to improving the quality of life for People with Parkinson's disease.

Broken String Bioscience’s technology platform, INDUCE-seq™, supports the development of cell and gene therapies that are safer by design. INDUCE-seq™, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs

C3 Biotech emerged out of the Manchester Institute of Biotechnology in 2015 by founders Professor Nigel Scrutton FRS and Michael Smith. They were driven by a vision to create a better world by providing sustainable and innovative solutions to meet the impending energy crisis. This vision is rooted in foundational science that has emerged from the engineering of biology, but is shaped by the need to urgently establish industrial manufacturing at scale. This idea is at the heart of C3. Building a better world doesn't mean reimagining what we do but the way we do it – sustainable fuels that clean up the planet and save natural resources is the first step in achieving global net zero goals, whilst tackling the impending energy crisis. C3 is now positioned to grow its pioneering technology to be catalysts of industrialisation in biomanufacturing.

Caldan, a spin-out company from the Universities of Glasgow and Southern Denmark, is developing novel therapeutics targeting free fatty acid receptors for NASH, Type 2 Diabetes (T2D) and other potential indications. Caldan has arisen from a long-term collaboration between Professor Trond Ulven at the University of Southern Denmark and Professor Graeme Milligan of the University of Glasgow.

Cambridge Nucleomics is a biotechnology company that specializes in fast and easy RNA measurement at scale with single-molecule accuracy.

Cambridge Protein Arrays Ltd. is a SME founded in 2010 and located in Cambridge, United Kingdom. We offer products and customised services in the area of protein microarrays and related areas. We are the distributors of HuProt™ arrays, the largest human protein arrays available, with more than 23,000 human proteins, representing 80% of the human protein coding genome, on a single slide. HuProt™ arrays have been successfully used for antibody and small molecule specificity screening, autoimmune antibody profiling, and interactomics. Cambridge Protein Arrays Ltd. also offers customised protein array services for high throughput screening, autoimmune biomarker validation, and tailored consulting services in the microarrays and antibody area.

Cambridge Research Biochemicals is a biotechnology company that specializes in custom-made peptide and antibody tools.

Carcinotech provides comprehensive solid tumour research services to therapeutic developers and healthcare professionals. At the heart of its offerings is the proprietary Carcino3D™ bioprinting platform, which creates assay-ready, 3D tumours from patient biopsies. Unlike conventional cancer models, Carcinotech’s bioprinted constructs incorporate multiple cell types—including immune cell populations—within a robust tissue matrix, offering a more biologically relevant and controlled model for early drug discovery, preclinical and co-clinical studies, and personalised treatment testing.

CardiaTec is a TechBio company employing computational methods to decode the biology behind cardiovascular disease. We leverage large and high-dimensional human omics data to better navigate complex disease biology to discover novel and differentiated therapeutics.

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions. Our Website: https://www.caristo.com Follow us on Twitter: https://twitter.com/CaristoHeart

Carta provides advanced genomic testing for IVF. We help IVF parents predict their embryo's disease risk and health outcomes in advance, resulting in improved women's health and healthier babies.

Maintaining musculoskeletal health is the keystone of overall health as we get older. As we age our physical condition gradually deteriorates, leading to loss of strength, fitness and mobility. In most cases, this isn’t due to a simple decision to stop exercising. It is due to the breakdown of musculoskeletal function caused by disease. Musculoskeletal diseases such as osteoarthritis, tendinopathy and lower back pain are the primary causes of disability and early retirement in people over the age of 65. Currently, there are no approved disease-modifying drugs for these diseases, meaning that physical decline in old age is inevitable. At Causeway, we believe that physical decline in old age is not inevitable and in indeed may be reversible. To address this, we are developing a range of therapies that treat common MSK diseases that will allow us to remain fit and active into our nineties and beyond. Staying active as we get older also reduces the risk of developing osteoporosis, dementia, diabetes, obesity, cancer and cardiovascular disease.

Synthetic biology is changing the way we think about diagnosing and treating microbiome-based diseases. At CC Bio, we harness the power of synthetic biology to engineer and edit the microbiome with surgical precision. Our goal is to eliminate microbiome-based disease in a potent, specific and prophylactic fashion, harmonising the relationship between eukaryotic and microbial cells. By considering the lifestyle needs of our patients, and understanding each microbiome-based disease holistically, we are elevating this fundamental aspect of human health out of the antibiotic era, putting power back in the hands of the consumer.

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of cannabis-based products, initially for the chronic pain market.

Celentyx Ltd is a ‘boutique’ CRO providing bespoke drug discovery services focused on human immunology across a broad range of therapeutic areas including autoimmunity, COVID-19, inflammation, immuno-oncology, fibrosis and neuroinflammation. Celentyx has a highly experienced scientific team that develops and provides assays using human primary cells at all stages of the drug discovery pipeline. Situated in close proximity to major hospitals and blood services (with established partnerships), assays can be performed at scale using blood and tissue from healthy volunteers and patients with defined disease including deep access to their clinical records. Celentyx has well-established assay platforms in multi-colour flow-cytometry, Cytof, high-content imaging, multiplex supernatant analysis (Luminex), super-resolution microscopy as well as proteomic and molecular biology capability, enabling high-resolution analysis of the human immune system for target discovery, screening, candidate selection, mechanism of action, and biomarker studies. Celentyx is based in the UK (Oxford and Birmingham) and in addition to internationally recognised scientists within the company, benefits from the world-leading expertise of neighbouring translational medicine departments at the Universities of Oxford and Birmingham.

The Offshore Renewable Energy (ORE) Catapult forms part of an elite network of eight technology and innovation centres established and overseen by Innovate UK, which represents a £1bn public and private sector investment over the next five years. ORE Catapult is the UK's flagship technology innovation and research centre for offshore wind, wave and tidal energy. We deliver prioritised research underpinned by world-class test and demonstration facilities, collaborating with industry, academia and Government to reduce the cost of offshore renewable energy and create UK economic benefit.

Inobrodib is the first small molecule drug in the clinic targeting twin proteins p300 and CBP. It is formulated as a capsule taken orally. p300/CBP are twin (paralogue) acetyl transferases, and importantly, gene activating proteins that are known to play an important role in the progression of certain cancers. CellCentric’s pioneering drug is in Phase I/II clinical trials to evaluate its effectiveness to treat specific solid tumours, as well as haematological malignancies (blood cancers). These represent major clinical unmet needs, delivering a new therapy for people with cancer, who otherwise have few alternatives.

Cellesce Ltd is a biotechnology company based in Cardiff, Wales, that focuses on organoid research and bioprocessing technologies. Established in 2013, the company specializes in patient-derived organoids (PDOs) for cancer research, utilizing patented bioprocessing technology to standardize and scale organoid production. The company offers several core services, including the development and manufacturing of standardized cancer organoids for large-scale applications such as compound screening and high-throughput drug discovery. Cellesce also provides scale-up solutions to ensure reproducible organoid batches, meeting the needs of pharmaceutical testing. Additionally, it supports drug discovery pipelines with customized organoid models, particularly in oncology. In December 2022, Cellesce was acquired by Molecular Devices, enhancing its capabilities in integrating organoid technology into drug discovery platforms. The company reported $7.8 million in annual revenue for 2024 and operates with a small team, emphasizing its commitment to advancing organoid-based precision medicine.

Manchester Biogel PeptiGel products are now part of Cell Guidance Systems. PeptiGel technology allows us to offer a family of high-quality peptide hydrogels, with a range of mechanical and functional properties, to enable you to find the most suitable materials for your application needs. PeptiGel hydrogels mimic the cell micro-environment and provide a natural physiological extracellular matrix that open up exciting new opportunities within the fields of 3D cell-culture, 3D bioprinting, regenerative medicine and medical devices to solve current healthcare challenges. Our technical support is available to help you realise your research ambition.

We are a UK-based company specialising in manufacturing and worldwide supply of consumables, equipment, and services to the cellular pathology sector. The CellPath name is synonymous with innovative, precise and well-proven products manufactured to a very high standard. We have a state-of-the-art injection moulding capability at our headquarters in Wales, allowing us to differentiate ourselves in the marketplace by directly manufacturing many of the plastic products used in modern histology and cytology laboratories. Expansion and infrastructure investment over recent years have increased our manufacturing capability, allowing us to introduce additional products to the market such as chemicals, stains, tissue marking dyes and fixatives. CellPath has a continuous improvement process built around a strong desire to maintain a high level of quality, and we are currently certified to ISO 13485:2016 standards.

Cellsway is a fresh deep-tech start-up founded in March 2020 in UK to convert the know-how and cutting-edge core technology that have been developed and cultivated at Mikro Biyosistemler Inc. into commercial products to set the gold standard for diagnosis and management of cancer. The flagship product of the company is a liquid biopsy platform which uses a simple blood sample for cancer diagnostics and cancer research. The patent-pending microfluidic technology enables isolation and enumeration of Circulating Tumor Cells (CTCs) from the blood samples of cancer patients.

CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol. We're working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world. Our mission is bold and ambitious and we have the best investors behind us from day 1. We're backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We're also supported by the founder/CEO of Abcam, which pioneered the antibody business.

Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity"​ in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ assets include specific leads and platform chemistry that is protected by strong IP and a family of granted patents and applications.

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company’s preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.

CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research Centre at the University of Nottingham. CHAIN has developed a proprietary microbial platform for drug delivery. The platform builds on core engineering skills and involves the development and use of engineered Clostridia to deliver specific therapeutics to the gut. CHAIN’s Clostridium Assisted Drug Delivery (CADD™) delivery platform is highly differentiated and supports a therapeutic product pipeline for a wide range of clinical indications including localised infection, inflammation and CNS signalling. Our lead asset is an engineered strain that secretes a novel and potent anti-inflammatory molecule targeting Inflammatory Bowel Disease, a chronic gut disease affecting millions worldwide.

CHARM Therapeutics is discovering and developing small molecule medicines against difficult-to-drug targets with our proprietary 3D deep learning-enabled platform, DragonFold. Powered by the first high throughput protein-ligand co-folding algorithm and a world-class team of scientists and engineers, CHARM seeks to deliver innovative approaches to create life-changing therapies for patients.

Pharmaceutical Services

By mining the genome using our bioinformatics platform we discover and re-purpose natural gene regulatory elements, creating customised gene expression systems to: 1. Improve human health: Creating highly selective and controllable promoters and gene expression cassettes for novel gene and cell therapy systems. Improving the efficiency of biologics production by increasing protein yields in upstream manufacturing processes. 2. Engineer biology: Harnessing synthetic biology to make promoters for a wide array of chassis organisms used in Industrial Biotech. Creating switches and gene circuits that can be employed in the metabolic engineering applications. 3. Enable traits discovery: Designing tissue-selective plant synthetic promoters active across different crop species for Agricultural Biotech applications. Using plant genomics to facilitate the design of environmentally-regulated and pathogen-responsive promoters.

Chromocyte is a FREE impartial and innovative online resource for designing complex multi-parameter flow cytometry antibody panels and finding the reagents and antibodies that are required for these and other related techniques. Chromocyte includes intuitive interfaces which highlight the latest flow cytometry products and services and will be an invaluable sales and marketing vehicle for those supplying flow cytometry related products and antibodies. Users can input the configuration of their own flow cytometry instruments and search for antibodies in the context of these. We also have a Core Facility Administration Area which allows flow cytometry configurations to be shared by Users in the same facility. We also offer a unique interface for generating antibody search panels - a great time saver! Chromocyte is somewhat unique in that is is based on the solid and developing academic background in flow cytometry of its Founder. We can therefore provide invaluable insights into current developments and the specific needs of the academic and research communities.

Chronos is a CNS specialist company with a high concentration of expertise in both degenerative and behavioural diseases of the brain and nervous system. What we do: Chronos is an Oxford-based biotechnology company operating a semi-virtual R&D model to develop a portfolio of therapies in degenerative and behavioral brain diseases. The team utilises a network of industry- leading contract research organisations to develop NCEs and repurpose existing launched drugs. Chronos also has a dedicated laboratory in Oxford which screens for activity of drugs in brain disease through its proprietary platform, Chronoscreen™. Our Focus: - Acquisition, discovery and development of novel proprietary lead candidates. - Repositioning FDA/EMA approved drugs. Targets: - ALS (Lou Gehrig’s Disease) - Other Neurological Diseases - Fatigue - Addictive Behaviour

Cirdan designs, manufactures and supplies innovative software and imaging solutions for the acceleration and enhancement of diagnosis. Our systems are optimised for pathology and clinical laboratory usage. Cirdan's primary product is its world-class Laboratory Information System, ULTRA. ULTRA has been designed to streamline laboratory operations and is currently installed in more than 72 laboratories across 6 continents. Another core product is PathLite Compact, a purpose-built system designed specifically for gross imaging within clinical laboratories. The company was founded in 2010 and is headquartered in Lisburn, Northern Ireland and has additional offices in Canada and Australia. Cirdan is also responsible for organising Pathology Horizons, an annual and open CPD conference on the future of pathology. For more information visit - www.pathologyhorizons.com

Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit clarivate.com.

A leader in next-generation prebiotic galactooligosaccharides (GOS), Clasado Biosciences is your partner of choice for scientifically supported prebiotic product development. Established in Reading, United Kingdom in 2004 and celebrating almost two decades of scientifically backed prebiotic expertise, Clasado is the team behind multi award-winning ingredient, Bimuno® GOS, a prebiotic trusted by health and nutrition brands worldwide. The ingredient's capabilities for improving health and well-being are supported by more than 120 publications, giving it the most comprehensive research portfolio of any commercially available GOS. These publications demonstrate how it can support health in areas such as gastrointestinal, immune and cognitive health across various applications from supplements and medical nutrition to functional food and beverages. Highly stable, with a low efficacious daily dose, and health claims available in specific geographies, Bimuno GOS offers premier levels of added value to formulations. Clasado is also the developer behind a range of finished D2C prebiotic supplements, including Bimuno Original (rebranded from Bimuno Daily) which support better everyday health, from the gut.

Cambridge Medical Robotics was created to bring the benefits of minimal access surgery to millions more patients each year. The company'saim is to make minimal access surgery available to all by delivering a robotic tool that empowers surgeons and delivers value-driven outcomes for healthcare providers.

CN Bio is a leading organ-on-a-chip (OOC) company that enables researchers to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® suite of microphysiological systems, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Intestine/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment and function of their human counterparts in vitro. The approach provides a viable alternative to animal models where translatability to humans is predicted to be poor and for testing advanced drug modalities where human-specific targets and pathways are required. They generate physiologically relevant, human-translatable, mechanistic data that enables researchers to progress only the safest and most efficacious drugs into in vivo animal studies and be better prepared for clinical trials. Please follow us for regular updates. It starts here.

Cobra Biologics, a Charles River company, is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply. The team at Cobra's GMP approved facilities has expertise tailored to serving customers around the world; offering a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market. As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.

Coding Bio unites a high throughput wet lab and ML platform to screen, build, and deliver fully-assembled modular therapies like CARs and BiTEs in only months.

Making Medicines More Manageable At Colonis, we repurpose medicines to make them more manageable for patients. By identifying and understanding how unmet clinical needs impact patients, we develop innovative solutions that improve compliance and enhance health outcomes, empowering individuals to live their lives to the fullest. Our mission is to support patients in receiving the most appropriate and accessible treatment for a better quality of life.

Colorifix usessynthetic biology to engineer microbes toconvert agricultural by-products into dyes.The dyeing industry is one of the largest water consumers in the world, using over 5 trillion litres per year along with petrochemical dyes and a host of toxic and highly polluting chemicals. According to the World Bank, textile dyeing accounts for around 20% of global industrial water pollution. Textile dyeing pollution uses up to 1.2 kilos of chemicals per kilo of fabric, only 50 grams of it being dye. Approximately 70 highly toxic chemicals are routinely used in textile processing, and up to 30 of them are irretrievable.

We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first clinical development programme is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. We want to transform the patient experience in mental health care.

Starting with a vision to truly take paternity testing to the general public, Complement Genomics has been bringing forward new DNA testing services since 2000. Working in areas as diverse as clinical trials and non-human DNA testing, the highly trusted company has considerable expertise in pharmacogenetics. Complement Genomics also provides COVID-19 testing for private clients and businesses. Operating from the Durham Genome Centre, Complement Genomics has developed different brands according to the market segment: - dadcheck®gold - DNA testing services for professionals, including solicitors, barristers, local authorities and social services - dadcheck®silver - a full range of DNA testing services for the general public, including paternity and other human relationships, for the determination of parentage, for immigration DNA tests or for DNA tests which are suitable for other legal purposes - Chxout - services designed to serve the non-human DNA testing market – for citizen scientists and professionals alike. Bat Species Identification | Bird Sexing | Bird Species Identification | Bird Parentage | DNA Barcoding of animals, plants and fungi - Geneblitz - designed to serve the CRO and pharmaceutical sector with genotyping and phenotyping for clinical trials - That DNA Company - an online value brand providing DNA testing services, primarily paternity tests, for the general public

Concinnity is developing an AI-driven RNA design platform to build gene control systems for gene and cell therapies. Our RNA-based control systems will form part of the gene therapy cassette and enable precise control of therapeutic activity. Such control systems have huge potential to enhance both patient safety and therapeutic efficacy, for example by allowing a gene therapy to dynamically adjust its activity in response to patient disease state, recognise tissue type, or by allowing clinical control of the therapy after administration.

Congenica is a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale. We drive Precision Medicine and help reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide. Congenica’s Platform is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, and is uniquely placed to drive ubiquitous use of complex data in routine clinical care. Our products and services are consolidated on one single scalable, automated analysis and diagnostic platform that encompasses inherited disease, somatic cancer, pharma insights and pathogen surveillance. Congenica was founded based on pioneering work at the Wellcome Trust Sanger Institute and the UK NHS. We are the exclusive clinical decision support partner for the NHS Genomic Medicine Service and have a global footprint supporting leading international laboratories, academic medical centres, hospitals and biopharmaceutical companies.

Consone AI a disruptive technology platform targeting how decisions are made in the drug development process. Accelerating new medicines to market, reducing cost, reducing preclinical toxic trials, time and environmental footprints. The Consone AI platform will empower user decision making by successfully predicting toxicological effects and viability of new drugs.

With the power to skillfully write meaningful DNA sequences, we embark on a new era where precise control over biology and the manipulation of matter in our environment is possible. Constructive Biology is a spin out from the laboratory of Prof. Jason Chin at the MRC Laboratory of Molecular Biology in Cambridge. Our platform allow us to fundamentally reprogram the genetic code, and make molecules that nature could not make before. We will use our technologies to biosynthesize new classes of enzymes, pharmaceuticals and biomaterials. If you would like to join our team, get in touch!

At Convatec, #ForeverCaring is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. #ForeverConvatec

Founded in 1946 in Nottingham, UK, Copley Scientific remains family owned and managed. We are recognised as the world's leading manufacturer of inhaler test equipment, in addition to being a trusted provider of test instrumentation for other pharmaceutical dosage forms including tablets, capsules, transdermals, semisolids, powders, suppositories and detergents. Copley continues to work closely with industry groups and leading experts to bring relevant new products to market, with all equipment backed by expert training and lifetime support. Committed to excellence, Copley aims to deliver exemplary service for an outstanding customer experience. With over 1,200 customers across 96 countries, including 9 of the world's 10 largest pharmaceutical companies, Copley prides itself on the highest quality products and service. It also remains true to its founding principle of meeting customer requirements through continuous innovation, over 75 years on. Visit www.copleyscientific.com for further information.

As a leader in orthopaedic innovation, Corin has pioneered a number of landmark developments since its foundation and is proud to have been able to improve the quality of life of thousands of patients around the world through these groundbreaking products. The company's talented and dedicated teams share a common commitment to deliver quality orthopaedic products and services to patients, surgeons and healthcare providers which exceed expectations and positively impact lives. With an increasingly active and demanding patient population, the need to provide state of the art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin's product portfolio is designed to provide each patient with the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance.

Corryn Biotechnologies is developing a technology to fabricate and deposit biomimetic nano- and micro-fibrous wound dressings directly upon wound sites at the point of care. This technology aims to significantly reduce the drawbacks of current commercial products and their lack of regenerative properties. These dressings have been shown to be formable from several different material platforms both with and without additives known to be beneficial to wound healing. Our technology comprises an in-house developed handheld applicator device, loaded with sealed sterile cartridges of proprietary material formulations which are converted to fibrous substrates through a process known as electrospinning and deposited painlessly onto the patient.

At Crane Biosciences, we enable RNA treatments for incurable diseases. We are based at Imperial College London and backed by Norrsken, InnovateUK, Entrepreneur First, and Creative Destruction Lab (University of Oxford).

At Creo Medical we are dedicated to improving patient outcomes by bringing advanced energy to therapeutic endoscopy. Our integrated electrosurgery unit delivers Bipolar Radiofrequency for precise dissection and resection and Microwave energy for controlled ablation and coagulation. This technology sets a new standard for Endoscopic Submucosal Dissection with our new Speedboat RS2 instrument: the Bipolar Radiofrequency cut allows precise dissection and the microwave coagulation provides controlled haemostasis while the protective hull reduces the risk of muscle damage and the integrated injection needle helps to maintain submucosal lift without instrument changes.

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel half-life extended CD137 x PSMA Humabody for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991). CB693 is a half-life extended CD137 x MSLN Humabody and is the second proprietary clinical candidate from Crescendo’s T cell enhancing pipeline. Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody. The Company’s ability to develop multi-functional Humabody therapeutics is based on its unique, patent protected, transgenic mouse platform generating fully human VH domain building blocks (Humabody VH). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel pharmacology and superior bio-distribution. This can lead to larger therapeutic windows compared to conventional IgG approaches. Humabody-based formats can also be applied across a range of non-cancer indications. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab for ZL-1102 (formerly CB001, an anti-IL-17A targeting Humabody), which is expected to enter global Phase 2 clinical development in patients with psoriasis. Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.

CryoLogyx specializes in developing and producing high-quality, cryopreservation solutions. The cryopreserved cells are designed to cater to the critical needs of the drug discovery, which is powered by the patented formulation - Cryoshield™. Freezing and thawing processes can be particularly stressful for cells, often resulting in reduced viability and recovery due to ice crystal formation and other factors. And the repetitive tasks of cell culture, including numerous counting and handling procedures, take significant time that researchers could otherwise dedicate to more critical aspects of their research. At CryoLogyx, we are building a future where assay-ready cells are the default option in cellbiology, and research outcomes are accelerated by weeks and months using products that enable experimental reproducibility and unparalleled ease of use.

Cumulus Neuroscience is a global digital health company focused on advancing neuroscience clinical trials and research. They collaborate with leading global pharmaceutical companies to meet the industry's complex clinical trial needs. Cumulus Neuroscience offers a unique career and is known for its innovative assessment platform for identifying brain disorders.

We are building a genetic therapy platform to develop curative solutions for peripheral nerve disorders starting with Neurofibromatosis type 1

Our mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged. Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes. We are deploying our innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets.

Healthcare needs to be reinvented. Our mission is to shorten patient journeys and medical workflows, powered by an internal EHR ecosystem. Our vision is to change healthcare to make it more accessible, decentralised and efficient through combining strategy, economics and digital. Cw1 believes in equality and it is committed to make a difference. Visit us at www.cw1.com or just see you around.

We are redefining digestive health by pioneering non-endoscopic diagnostics, enabling early detection of diseases and access to care for everyone, everywhere.

Cytocell is a biotechnology company that specializes in designing and manufacturing a variety of fluorescence in situ hybridisation (FISH) probes.

Providing predictive analytics from suspended-cells through our unbiased cytometry technology, AuraCyt™

Pioneering the next generation of precision medicines to deliver a portfolio of transformative cancer therapies. Dark Blue Therapeutics is an innovative drug discovery biotechnology company based in Oxford, UK. We have assembled a highly experienced team, whose expertise spans the breadth of drug development from discovery to approval. This expertise has been gained over many years in the industry and draws from biotech, large pharmaceutical companies and investment management. Dark Blue leverages ground-breaking cancer biology insights, from Oxford University, to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. With this deep, proprietary understanding of target biology we match our precision medicines to molecularly defined patient populations to develop transformative, durable drugs that address critical unmet patient needs, delivering medicines that transform the outcomes for cancer patients. We work across a variety of biological mechanisms to identify and pursue only cancer targets that have the highest transformative potential.

At Aerbio, we’re powering the future of fermentation technology. We utilise hydrogen and carbon dioxide, instead of sugar, to fuel the creation of a range of products. Leading the charge with our groundbreaking single cell protein, Proton™, we are boldly redefining sustainability and innovation in industrial biotechnology.

We are a big-data and analysis company focused on enabling reproducibility and predictability in chemistry. With machine learning (ML) and AI powered products, SmartChemistry® empowers the chemist to design, experiment and understand their chemistry on an unprecedented scale. Utilising an advanced knowledge base that combines reaction data, real time sensor data and outcomes, SmartChemistry® enables access to a higher level of experimentation in the chemistry laboratory.

DefiniGEN are a Cambridge UK company providing highly functionalhuman cell productsincludingliver, pancreas, lung,and intestinal cells pluscustom servicesfor drug discovery and disease model generation.

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COVTM, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects. For further information on the company, please visit www.destinypharma.com

Diabetes currently effects over 537 million adults worldwide, with obesity-driven Type 2 Diabetes accounting for over 90% of cases. Dia Beta Labs build on over 30 years of high-impact research from our founding research group at Ulster University to realise the potential of next-generation therapeutics for metabolic disease. It is our goal to impart significant and much-needed change in the management of the global diabetes/obesity crisis.

DiagNodus is a biomedical research services company that specializes in pathology and molecular biology, offering laboratory-based projects, research design, clinical trial services, and sample analysis.

DIOSVax is a biotech startup working to revolutionise the way humanity protects itself from infectious disease and emerging pathogens. The company is named after its core technology, DIOSynVax (Digitally designed, Immune Optimised Selected and Synthesized Vaccines), a new system that will significantly accelerate vaccine development and achieve dramatic improvements to the protection against emerging and re-emerging pathogens.

DJS Antibodies acquired by Abbvie (10/20/22) DJS Antibodies was founded upon a vision of creating the next generation of antibody therapeutics. The company is dedicated to developing novel therapeutics to treat chronic inflammatory diseases through the discovery and development of antibodies.

DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring. It is developing the LiDia-SEQ™ system, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide comprehensive, actionable information to clinicians in a matter of hours, versus days. DNAe’s initial focus is on infectious disease diagnostics, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to directly detect and identify infections that lead to sepsis. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease. A pipeline of follow-on tests is in development for viruses and cancer testing and monitoring. DNAe has received “Breakthrough Device” designation from the US Food and Drug Administration (FDA) for its pioneering platform and first assay. Headquartered in London, UK, DNAe has expanded operations further in with a clinical diagnostic development and manufacturing site in San Diego, CA. We are always on the lookout for exceptional talent. For more details, visit www.dnae.com. Or get in touch, we would love to hear from you. Twitter: @dna_electronics Instagram: dna.electronics

DNA Worldwide is a specialist DNA, Hair Drug & Alcohol testing company providing a comprehensive range of home and legal DNA tests. DNA Worldwide concentrates on quality and customer service certified to ISO 9001:2008. It exceeds all UK and international requirements for testing through its ISO:17025 certified partner laboratory. All tests are dealt with discretely, efficiently and are subject to the highest levels of security with accuracy of 100%. A team of over 200 leading industry scientists is backed up by dedicated and supportive customer care, regularly dealing with paternity testing for family disputes, immigration testing as well as more complex testing of special specimens. The company also offers siblingship, Aunt/Uncle testing and Grandparent testing.

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. Combining a workflow and data platform with best-of-breed applications, we offer the first true end-to-end solutions for biology, chemistry, formulations, data management, flow cytometry, and more. Trusted by more than 2 million researchers from the world's leading biopharma, chemicals and materials enterprises, and academic institutions, we are dedicated to working with the scientific community to help make the world a healthier, cleaner and safer place to live. Learn more about our platform and products, including GraphPad Prism, Geneious, SnapGene, Protein Metrics, LabArchives, and more, at https://dotmatics.com.

Draig Therapeutics is a clinical-stage company with a mission to transform treatments in Neuropsychiatry. The company is leveraging its founders' unique scientific expertise in modulating the core glutamate / GABA pathways that play a critical role in neuropsychiatric diseases to advance a pipeline of groundbreaking therapies designed to address large unmet patient needs, including in Major Depressive Disorder (MDD). Draig is the Welsh word for ‘dragon' and it reflects the company's origins in Wales. The name and logo were inspired by this heritage, reflecting its scientific roots stemming from Cardiff University.

Dr Falk Pharma UK was established in 2005 to provide the Dr Falk organisation with its own company in the UK and Ireland. Dr Falk Pharma is a family owned business based in Freiburg, Germany developing medicine to treat a wide range of gastrointestinal disorders and hepatobiliary disorders for over 60 years. Guided by the Falk philosophy, Dr Falk UK is dedicated to improving patient outcomes through working alongside healthcare professionals, researchers and patients to develop therapies that work for people not just diseases. Dr Falk also facilitate educational events and support patient societies to promote shared learning. Now for the first time FalkPlus brings everything we do together in one place. Tap in and join the community no matter where you are in the UK by using the Register button above. We look forward to seeing you. Dr Falk Pharma UK's Social Media Policy: https://www.drfalk.co.uk/dr-falk-pharma-uk-social-media-community-guidelines/

Duke Street Bio is focused on exploiting tumour genetic vulnerabilities and harnessing the natural power of the body’s immune system to fight cancer.

Dunad Therapeutics is focusing on the development of next-generation targeted protein degradation therapies. Dunad’s platform enables selective degradation viadirect target modification using tuneable mono-valent small molecules, unlocking new target space and allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

Dyneval’s innovative technology provides precise measurement of semen quality using portable equipment. It is the first technology capable of measuring the lifetime of semen motility in quasi- in-vivo conditions, thus providing new insights into the behaviour of spermatozoa prior to conception. We are fulfilling our vision to become the experts’ choice for semen quality assessment. Vets and genetics companies are using this data to inform breeding plans and confirm quality at every stage across the supply chain to ensure that livestock production is more efficient, improving food security while reducing the intensity of methane emissions.

Eden Bio uses machine learning to improve protein yield, saving companies time and money, and helping them get their proteins to market faster.

The world's first non-invasive solution to treat and reverse cataracts. Our scientists have been working to develop a completely novel therapeutic approach to the treatment of cataracts based on the use of light rather than surgery or drugs. Cataracts develop slowly over many years and the gradual changes often go unnoticed at first. LEDINBIO uses light energy with specific wavelengths to reform the proteins in your eye which allows light to pass through allowing you to see clearly and brightly once again.

EKF is a leading global diagnostics and biotechnology company specialising in the development, production, and distribution of leading medical technologies and patient-centric solutions. Our diagnostic technologies and biotechnology solutions empower healthcare professionals and non-medical practitioners to make informed decisions through point-of-care testing and life sciences applications. Point-of-Care: EKF develops and manufactures medical devices and tests (in-vitro diagnostics (IVD)) that can be used at or near the patient's location. Designed to provide quick and accurate results, these tests (and optional data connectivity software) enable healthcare professionals to make rapid decisions. Diabetes care: EKF offers a range of products related to diabetes care, including glucose monitoring systems and associated supplies and consumables. Hematology solutions: EKF provides products, supplies, and consumables for measuring hemoglobin levels, including those used for the detection of hemoglobin variants. Life Sciences: EKF develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and other bio-materials used in the research, biotechnology, and pharmaceutical industries. Dedicated to supporting clinicians, scientists and researchers these high-quality materials can be used in multiple applications. Enzyme Fermentation: EKF offers precision fermentation, custom bioprocessing and contract manufacturing services related to the production of pharmaceuticals and other biologics. Beta-hydroxybutyrate (β-HB): EKF provides β-HB products which are used to detect ketones, to help identify patients suffering from diabetic ketoacidosis, and other clinical applications. As a global leader in the development and distribution of diagnostic technologies and biotechnology solutions, EKF has a presence in over 120 countries with the solutions needed to support better health and wellness worldwide.

Elasmogen is a therapeutic biologics company developing multi-functional products for difficult-to-treat diseases. The company has built a product pipeline that exploits the advantages of its proprietary, patent protected soloMER technology including first-in-class drug conjugates (SDC) and bi-specific products for the treatment of autoimmune diseases. Our oncology assets include a pipeline of differentiated soloMER-targeted RadioPharmaceutical Therapies (RPT) for the treatment of solid tumour cancers.

Eleven Therapeutics is a biotechnology company leading the AI revolution in nucleic acid therapeutics. They harness the power of combinatorial chemistry and AI to transform RNAi drug development into a programmable process.

Yourgene Health is a leading integrated technologies and services business, enabling the delivery of genomic medicine. Yourgene works in partnership with global leaders in DNA technology to advance diagnostic science. Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. Flagship in vitro diagnostic products include Non-Invasive Prenatal Tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping. Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger® Technology, the LightBench® and the LightBench® Detect instruments are ideal for cell-free DNA applications in NIPT, gene synthesis and oncology, including liquid biopsy. Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. Yourgene Health is headquartered in Manchester, UK with facilities in Singapore, the US and Canada. Yourgene is now part of the Novacyt group of companies. For more information visit www.yourgenehealth.com

EmstoPA is a first in class antibody-based reversal agent to treat bleeding caused by tissue plasminogen activator (tPA - Activase®, Alteplase®). tPA is a “clot buster” used to remove the blood clots that cause stroke, pulmonary embolism, and myocardial infarction. In the developed world, tPA is most frequently used to treat acute ischemic stroke where the rates of subsequent intracranial hemorrhage (ICH) are 5-7% . EmstoPA belongs to a class of drugs called anti-fibrinolytics, and and the current market for antifibrinolytics is estimated to be $1,100m /year. Currently no specific tPA reversal agents are in development.

Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover novel cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing database of Dark Antigens that can address the unmet need for cancer-specific targets that are homogenously expressed and highly prevalent in solid tumors. We are advancing multiple approaches to exploit these Dark Antigen targets, with an internal focus on TCR-directed immunotherapies, and additional therapeutic partnerships with Boehringer Ingelheim and another undisclosed global pharmaceutical company.

To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.

Enhanced Genomics is a pioneering functional genomics company harnessing its proprietary 3D genomics technology to transform drug target discovery. By integrating 3D genomics with multi-omics approaches, Enhanced leverages 3D Multi-omics to deliver unparalleled insights into gene regulation and disease mechanisms. This innovative approach accelerates the development of novel therapeutics across a wide range of disease areas.

Enigma Diagnostics is a PCR-based testing out of the laboratory with a range of simple-to-use products.

Ennogen is a privately owned British company offering a range of medicines, medical devices, and unlicensed medicines. It was founded in 2011 by CEO John Ruprai.

Our patented novel Ensilication technology uses silica to create an individually tailored protective nanoshell around vaccines, antibodies and enzymes to prevent degradation, which can lead to spoilage. Once applied, the material can be stored and transported without the need for cold chain infrastructure, improving global access to medicines and reducing wastage and emissions across the pharmaceutical supply chain. Ensilication preserves the integrity of a wide variety of biomolecules and proteins, not only protecting against environmental degradation, but also making possible the development of more convenient administration such as subcutaneous and oral delivery for both humans and animals. We are actively looking for partners to work with us in developing ensilicated products, free from cold chain dependence. Please don’t hesitate to contact us if you’re interested in finding out more about us, and how our technology may benefit your products.

EnteroBiotix is a leading microbiome therapeutics platform company that is focussed on transforming the standard of care for patients battling debilitating diseases and infections linked to disruptions to structure and function of the gut microbiome.

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.

Designer Sponge RNAs for Cellular Health Restoration

Epistem Ltd. is a leading contract service provider offering innovative preclinical research services, genetic and protein biomarker testing as well as histology services to pharmaceutical, biotech and academic customers to support to drug discovery and development pipelines. We have worked with over 200 pharmaceutical and biotechnology companies at both preclinical and clinical stages. Our high level of expertise and customer focus has led to an enviable track record and impressive amount of repeat business. Our preclinical contract research services group advance drug development programs for oncology, inflammatory, dermatology, auto-immune and GI disease indications. We offer an impressive range of preclinical models in these therapeutic areas. We also provide information relating to toxicity assessments and are experts in GI tox. We also offer a broad range of cell based assays including novel stem cell assays. Our biomarker services division offers GCLP compliant genetic testing, histology, FACS analysis and protein biomarker detection. Epistem’s genetics group offer gene expression and DNA genotyping sample analysis by NGS, microarray and qPCR. We specialise in working with small starting materials (down to a single cell input) applying our proprietary low input techniques and products to support drug development programs. We are specialists in fractionating cell populations and conducting genetic analysis. We have pioneered techniques using plucked scalp hair and laser capture microdissected material to provide gene expression biomarker information to drug development programs. Epistem is committed to provide reliable and innovative services to support all phases of drug development from to preclinical projects to clinical trials. Website: www.epsitem.co.uk

Epoch's biorecycling platform unlocks circularity for the toughest-to-recycle materials. Our AI-designed enzymes enable infinite recycling for mixed plastics and textiles at low temperatures. We produce sustainable outputs for use in apparel, automotive, packaging and more.

Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.

Esox Biologics utilises their extensive knowledge of the aquatic microbiome to provide disease prevention solutions that help improve livestock health and welfare.

Neurodegenerative disorders present a huge societal burden, and one from which few of us remain untouched in some way. Unfortunately, by the time a diagnosis is made, it is often too late and irreversible damage is already done. It is essential that patients get examined as early as possible, and that symptoms get diagnosed accurately. This allows the right patients to receive the right treatments at the right time, to help to slow progression, and mitigate symptoms. Pharma and Biotech companies that are developing disease modifying therapies also have a need for biomarkers for neurodegenerative disorders that can help predict disease presence, monitor disease progression and treatment response. ESP Diagnostics is developing scalable liquid-biopsy tests based upon measurements of specific neurodegenerative disease biomarkers in extracellular vesicles (EVs) extracted from blood, saliva and urine. The ESP biomarker tests will allow early pre-symptomatic detection of neurological disorders such as Parkinson’s Disease, Dementia with Lewy Bodies, and a differential diagnosis of Alzheimer’s. We provide assay services to pharma and biotech companies developing disease-modifying therapies (stratification, disease progression, surrogate endpoints, reverse translation, target engagement), and are developing IVD products for patients, clinicians and healthcare providers worldwide.

Essential Pharma is an international specialty pharmaceutical company dedicated to maintaining access to clinically differentiated, niche medicines in small patient populations. Our high-impact portfolio has a focus on the central nervous system (CNS), gastroenterology, ophthalmology, and rare disease, and our products treat patients in more than 70 countries. We are proactive in identifying low volume, difficult-to-manufacture therapeutic products, and late-stage clinical development assets that target rare diseases. We specialise in the acquisition of mature, established, branded medicines that are at risk of shortages or discontinuation, working with partners across the globe to ensure their continued manufacture to the highest standards. Essential Pharma comprises innovative and driven people who are passionate about ensuring continued supply of medicines to patients. We are committed to living by our values – Collaborative, Responsible, Trustworthy and Dynamic – and pride ourselves on our inclusive culture, where everyone's voice is valued and respected. We have an unwavering dedication to employee growth and believe in fostering an environment where all individuals can thrive.

Etcembly’s vision is to decode immune repertoires for health and disease. The TCR repertoire holds the answers to therapeutics and biomarker information, and Etcembly is assembling the world’s largest health and disease immune database, to revolutionise immunotherapy and personalised therapeutics across all patient groups, globally. We are pushing the frontiers to explore the intersection between immunology and machine learning.

A specialist in computational drug discovery with a focus on developing RNA interference (“RNAi”) therapeutics

Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease. Our pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.

At Evolutor we have developed a suite of proprietary technology and microbiology to unlock the potential of evolution beyond current possibilities. Using our innovations, Evolutor will accelerate the development of commercially viable microbial factories across a huge range of industries. We are on the brink of The Bio-industrial Revolution, and Evolutor is positioning itself at the front line of this paradigm shift.

Evonetix is set to revolutionizede novogene synthesis to facilitate the fast-growing and exciting field of synthetic biology.The company's unique selling point is driven by high fidelity and parallelization of gene synthesis.Evonetix's technology is based upon a novel silicon array, manufactured with semiconductor microfabrication techniques and capable of independent control of 10,000 miniaturized reaction sites, allowing massive parallelism in the DNA synthesis process and therefore very high throughput.

Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs. Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics. Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.

eXmoor is a full service Cell & Gene Therapy CDMO with a difference. We are backed by 20 years consultancy experience supporting over 150 organisations accelerate novel therapies from discovery to patients. We provide expert solutions at all stages of the development journey from early process development and scale-up through to GMP manufacture, fill and finish and QP release. We are open, transparent and will work with you at every step to de-risk and streamline your project and maximise the chances of product success.

Getting genetic syntax right. With precise use of genetic grammar in transgenic design, ExpressionEdits unlocks the capacity to make proteins previously beyond reach.

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiates the orotomides from the currently marketed antifungal agents. Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mould infections including a variety of rare and resistant moulds that cause life-threatening infections for which current therapies have limitations or are ineffective. Olorofim is in a Phase 2b open-label study focusing on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis and scedosporiosis (including lomentosporiosis). Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation and Breakthrough Therapy designation from FDA. F2G is headquartered in the UK with subsidiaries in the US and Austria.

FAST BIOPHARMA LTD is a company based in Aston Rowant, Oxfordshire, UK

The NGX 124 is a compact, ultra-fast, sample-to-result molecular diagnostics platform that runs extracted nucleic acid (NA) or direct qPCR assays. It features a 4-channel thermal cycler with highly thermally conductive 96 well SBS format microtitre plates. An onboard automated heat sealer ensures consistent sealing. Plates shuttle between dual heater blocks in ~1 second, with fluorescence captured mid-transfer for real-time analysis. Each run processes 4–92 patient samples, plus 4 controls. Aspiration is via the Pathtube® a UN3373-compliant sample tube with a pierceable cap. Two versions exist: one for 1ml direct qPCR; the other for 200μl extracted NA. Reagent-mixing algorithms reduce dead volumes, cutting waste. Intuitive software allows operation by lab technicians, reducing reliance on BMSs and freeing them for more complex tasks. The unit occupies 0.7m², is mounted on wheels, and installs in under 15 minutes. Output includes CT values, raw data, and filtered/unfiltered curves. Fast MDx is also developing AI tools for early detection of infection hotspots. Each NGX 124 can scale to 3,000 tests per day (across 3 shifts), supporting pandemic preparedness. An Open Platform Unlike closed systems from major manufacturers, the CE IVDR and UKCA-marked NGX 124 is open. Labs can run their own LDTs or CE IVDd assays, driving innovation, reducing costs, and widening access to automated qPCR globally. Commercial Models 1. Subscription – Free platform, servicing and consumables included; labs pay per test with a monthly minimum. 2. Outright Purchase – Labs buy the platform and consumables, with optional service contract. Labs retain freedom to use existing assay suppliers. Launching in the UK and EU in September 2025. Our Mission Fast MDx is a registered Social Enterprise with the aim todemocratise molecular diagnostics. We welcome collaborations with academics, charities, and funders to develop early detection screening programs that can transform global healthcare.

We are a Bioinformatics Provider with clients in the UK, Europe and America. With over 15 years of experience in supporting scientists, researchers and bioinformaticians in data analysis, we have an extensive experience in handling all types of datasets for drug discovery & development, diagnostics, agricultural research, veterinary medicine and applied research across all species. Our specialised team of bioinformaticians, statisticians and biologists are able to analyse and interpret any genomic, transcriptomic, proteomic & metabolomic data, independent of the platform used. We are very well appreciated among our clients for our proprietary computer solutions that allow parallelisation of large datasets analysis that saves processing time and avoids the complications that arise when analysing data in batches. Results of the analysis are always presented in a secure web report that is complete with all references and results. Types of services offered by FIOS: ● Technology/Platform Selection ● Study Design & Biostatistics ● Data QC and Pre-processing ● Biomarker Identification & Validation ● Genomic Signature Development ● Data Visualisation ● Preclinical Safety & Toxicology Investigations ● Clinical Trial Analysis ● Drug Repurposing For more info, get in touch: https://www.fiosgenomics.com/contact-us/ Twitter: @fiosgenomics Facebook: https://www.facebook.com/fiosgenomics/ Office Phone Number: +44 (0)131 322 3770 Office Address: Fios Genomics Ltd, BioCube 1, 13 Little France Road, Edinburgh BioQuarter, Edinburgh, EH16 4UX

Five Alarm Bio is a drug discovery company based in Cambridge, UK focusing on novel approaches to anti-aging, with broad potential therapeutic application. We are researching therapeutics that boost the body's ability to defend against the damage of aging.

NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates; this gives them enhanced stability for use in a variety of applications which address two of the world's major challenges, antibiotic resistance and food supply and sustainability. By attaching specific bacteriophages to fish and animal feeds, we can reduce, augment or even substitute for antibiotics in the food chain. This lets us target both human and animal pathogens, such as E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas, Flavobacteria and others. As our bonded phage products can be stable for months or even years and are less sensitive to temperature and other environmental factors, they can be effectively shipped and applied in versatile formulations Bacteriophages also have many potential human applications when antibiotics fail. Phages are expert microbiome engineers and can specifically alter the bacterial microbiome of the human gut, skin, vagina, lung and other micro-environments. Microbiome engineering has important applications to irritable bowel syndrome, acne, bacterial vaginosis and bacterial lung diseases. Our ability to attach bacteriophages to micro- and nano-particles and to enhance their stability and active life span, can potentially enhance their effectiveness in these applications, whether as part of a probiotic supplement or as encapsulated powders/beads.

Forcefield Therapeutics is a pioneer of best-in-class therapeutics to retain heart function via the protection of cardiomyocytes. Forcefield Tx was founded on the work of Professor Mauro Giacca, an authority in cardiovascular disease and genetic biology and the Heat of the School of Cardiovascular Medicine and Sciences at King’s College London as well as industry experts and investors with a shared purpose to revolutionise treatment following acute myocardial infarction (MI). Forcefield’s unique approach can both retain and protect heart cells, minimising the impact of MI and preventing the cascade of events that may lead to subsequent heart failure. Forcefield Tx is led by a proven team with a record of success from discovery to commercialisation and is backed by a leading FTSE 250 healthcare company, Syncona.

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

For over 30 years, FUJIFILM Diosynth Biotechnology’s mission has been advancing tomorrow’s medicine. As a CDMO, we work in partnership with the most innovative biopharma and biotech companies across the world who are reimagining healthcare’s potential. We help to accelerate their progress, expand their capabilities, streamline their processes, and strengthen their innovation. So when our customers’ potential cures, vaccines, biologics, and accomplishments make strides – or even become new realities for patients – we know our work, our manufacturing expertise, and our partnership helped make it happen. FDB isn’t simply a workplace. It’s a place of passion – a place of what we call Genki. A place where diverse perspectives and people come to life. Where opportunity for growth has no end. Where passion is followed, discovered, and nurtured. Where the energy is undeniable, enthusiasm is pervasive, and drive is infectious. All of our global locations burst with curiosity, inspiration, and extraordinary purpose. So as we continue to grow our teams, our global locations, and our capabilities, Genki will always be our cultural tie. That’s why we’re always looking for passionate, mission-driven people who want to commit their life’s work to enabling better outcomes for patients and their families. For a full listing of jobs that will propel, inspire, and fulfill you, please visit: fujifilmdiosynth.com/careers/ We created this space on LinkedIn to give people a window into work and culture at FDB. We’re highlighting employees’ passion, current openings, and why it’s never been a more exciting time to join FDB.

Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry. We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages. Fifteen of our client's projects have advanced to clinical stages, some as far as Phase II. We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics. We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development. Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™). Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.

genedrive plc is a molecular diagnostics company developing and commercialising a low-cost, rapid, versatile, simple to use and robust point of need molecular platform for use in patient stratification (genotyping). We are passionate about the opportunity to build a sustainable business around molecular diagnostics and to play an important role in the diagnostic and treatment challenges presented by global health issues. The company launched the Genedrive MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, which was co-developed with the partners in the UK's National Health Service and is now used for routine clinical use.

We are a molecular diagnostics company working predominantly in the fields of infectious disease, cancer diagnostics and personalised medicine. Our ethos is to offer robust easy-to-use, sensitive, and affordable molecular diagnostics technologies and products to researchers, clinicians and drug companies to enable accurate diagnosis and the delivery of safe and effective medicines. Our patented technologies allow for simultaneous detection of multiple targets in one reaction. If you have a project or collaboration in mind, we'd love to hear from you! Do you have a requirement for detecting multiple targets? Are you working with bacteria, viruses or fungus? We can help you achieve what you need with our dedicated team of experts. Drop us a line here or email us at info@genefirst.com

Genflow Biosciences plc (LON:GENF) (OTCQB:GENFF) is a UK-based biotech company with R&D facilities in Belgium and a U.S. office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results. Managed by an experienced team with decades of experience in the pharmaceutical and biotechnology sectors, the company is optimistic that development programs will continue at pace in the next 24 months.

GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient's genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients' health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.

GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient’s genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients’ health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.

GenomeKey enables targeted Sepsis treatment in hours, rather than days. This is important because Sepsis now kills more people than cancer. It can hit anyone, of any age, and kills within hours. A patient admitted to a hospital today, they wait 3 days before the doctor knows which antibiotic will fight the infection. We use cutting edge machine learning and DNA sequencing to bring 3 days down to just a few hours, with the only affordable test that provides a result for every patient. This saves lives, saves money, and saves our last antibiotics for when we really need them.

DNA is the blueprint to what makes you who you are. It is the most valuable piece of personal information an individual will ever own. It is an appreciating asset that will continue to increase in value as genetic research continues to unlock mysteries in DNA over time. However, as soon as individuals send their saliva to a sequencing facility and their DNA is read, they relinquish all control over their data. Organisations that hold this data currently do not have the technology to safeguard it from data hacks/breaches and many legally share DNA data in plain text to third parties in multi-million dollar deals. This means that individuals not only are excluded from taking part in any value their DNA may hold but lose ownership and privacy of highly sensitive DNA data. We at Genomes.io believe individuals should be able to own, control access to and benefit from their most sensitive and valuable personal asset, their DNA. We are building a secure DNA sequencing, storage and sharing technology using state-of-the-art encryption and blockchain technologies to provide users with control over their whole genome sequence. This allows users to control access to segments of their genome in a repeat consent model to trusted professionals and accredited researchers in a secure, private and anonymous manner. Our platform acts as genomic data aggregator that provides research organisations with a more efficient genomic data acquisition model. However, we do so in a more equitable model in which individuals own, control and get paid for the data they wish to share. We aim to securely sequence and store 1 billion individual’s genomes in our DNA data bank and become the world’s largest, most secure and trusted genomic and health data marketplace to power the personalised medicine revolution. Genomes.io - Invest in Future You.

We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).

Genpax is revolutionising infectious disease investigation with IDEM, our groundbreaking surveillance tool using whole genome sequencing analysis. IDEM uses precision genomics to uncover the true relationship between bacterial isolates, offering a comprehensive solution to strain identification and outbreak management. IDEM not only provides unrivalled accuracy and resolution to transmission events, but also provides healthcare professionals with markers of clinical significance, signalling the need for swift containment or patient review.

Gentronix is a specialist CRO focused on delivering predictive toxicology products & services to global chemical sectors. Working with companies from early screening through to regulatory safety assessment, we deliver innovative solutions for both genetic toxicology and skin sensitisation. For 20 years, Gentronix Ltd has provided predictive toxicology solutions to global chemical industries; enabling our clients to optimise their development programmes via early identification of genotoxic hazard and assessment of chemical safety. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity products & services, along with assessment of skin sensitisation potential.

Genus is a world-leading animal genetics company. At the forefront of innovation in gene-editing, advanced reproductive biology, and other breakthrough breeding technologies, Genus R&D advances an agricultural practice thousands of years old – animal breeding. Our goal is to ensure the global food system continues to nurture healthy, productive animals that yield affordable, high-quality proteins for a sustainable future. We believe a more sustainable food system starts with better breeding and genetics. Through ABS Global (bovine) and PIC (porcine), we supply high-quality breeding animals with desirable characteristics to farmers, enabling them to produce better quality meat and milk more efficiently to feed the world more sustainably. Our breeding animals’ desirable characteristics include feed efficiency, disease resistance, growth rate, protein and fat content, and fertility. ABS Global is the world-leading provider of bovine genetics, reproduction services, technologies, and udder care products. Marketing in more than 70 countries around the globe, ABS has been at the forefront of animal genetics and technology since its founding in 1941. In bovine genetics, ABS serves more than 40,000 customers globally, including some of the world’s leading beef and dairy producers. PIC, which stands for ‘Pig Improvement Company,’ was founded in 1962 in Oxfordshire, England. PIC strives to make their customers the most successful pig producers in the world and their “Never Stop Improving” philosophy means a continuous effort to listen carefully to customers and drive innovation to create ever-increasing value for pig and pork producers.

George Medicines is a late-stage drug development company focused on improving the management of non-communicable diseases with innovative, single-pill, fixed-dose combinations of existing medicines. Combining best-in-class molecules from existing medicines in fixed- and low-dose formulations, George Medicines is developing innovative and proprietary treatments that are more efficacious, safer and affordable than currently available treatment options. These single-pill, fixed-dose combinations offer the potential to bring significant improvements in clinical outcomes and therapy adherence in patients with cardiometabolic diseases such as heart disease, hypertension, and diabetes, which remain the leading causes of premature death and disability worldwide. George Medicines is building a strong and diversified pipeline of patented, single-pill, fixed-dose combination therapies in late stage development. Its lead candidate for the initial treatment of high blood pressure, GMRx2, has received clearance from the US Food and Drug Administration (FDA) to enter Phase III development. George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world's leading medical research institutes in non-communicable diseases.

Glen Clova Scientific Ltd (GCS) is developing a new generation of Active Biologics to treat inflammatory conditions. We are an ambitious spinout from the University of Dundee aiming to address the global need to make effective treatments available for millions of patients. Our novel Virus-Like-Particle technology is poised to address inherent limitations of the current blockbuster class of Biologic drugs. Our vision is to make high end biotech pharmaceuticals much more accessible to patients than current blockbusters. #Glenclovascientific #Dundee

In an increasingly fast-moving, complex, and uncertain world, it's never been harder for organizations and decision-makers to predict and navigate the future. Which is why GlobalData exists - its mission is to help clients decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Its solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

An introduction to GlycanAge® Our modern lifestyle has drastically changed the way we live and can impact our health for better or for worse. How can you gain a more complete picture of the current state of your health? Science has revealed a significant element that up until recently has largely been overlooked. Your biological age. While you have no control over the process of aging chronologically, your health and lifestyle can have a significant effect on your biological age. Your biological age is therefore not necessarily the same as your chronological age. Only about 54% of biological aging is determined by your genes, with about 46% being influenced by environmental factors. GlycanAge is a simple, ground-breaking test that analyses your glycobiology. Taking a GlycanAge® test is a vital step to improving your health. Your test results enable you to become aware of and monitor your biological age. This not only offers you an accurate insight into the current state of your health but can give you the powerful tool to make an informative decisions about lifestyle choices and changes.

Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery.

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Discovering and developing innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world.

Haoma Medica Ltd is a UK based biotech company that focuses on treatments for Osteoporosis and Osteopenia as well as blood clotting management. The Osteoporosis & Osteopenia drug referred to as NaQuinate and commercially as Osteopura, is a novel class of compound, designed for low dose oral administration. Being a natural product, that preserves both bone mass and bone architecture, the safety profile of the therapeutic approach has significant potential for the long-term treatment of the serious problem of osteoporosis. The therapeutics in Osteopura are present in all people, but only in very, very small amounts, Osteopura boosts the levels of these agents to preserve bone integrity. Haoma Medica Limited started with the platform of "working with nature and not against it". www.haomamedica.com

At Harness Therapeutics we have one mission – physiological upregulation of targets that have the promise to provide disease-modifying therapeutics for neurodegenerative diseases. We use a range of mRNA-targeted oligonucleotide-based methodologies to alter the post-transcriptional regulation of protein synthesis and so increase the target protein in a controlled manner. Our focus on neurodegenerative disease is driven by our passion to develop truly disease-modifying therapies for diseases that affect so many people, yet for which there are few if any therapies that can slow or halt the progression of the disease. The ability to effect controlled increases of protein levels is essential in being able to safely drug targets with narrow therapeutic windows, something that existing platforms cannot achieve. This is critical for neurodegenerative disease as there are now a number of targets that have strong genetic validation linked to disease progression but require controlled increases rather than knock-down or over-expression. Our goal is to open up the target space for neurodegenerative disease and be able to advance effective treatment solutions for the tens of thousands of patients and their families who are facing the certainty of irreversible disease progression, loss of quality of life, and ultimately death. Our name reflects our approach, built and refined since our formation in 2020; harnessing the body’s endogenous cellular processes controlling protein synthesis to achieve controlled increases in protein levels in the safest possible manner. We use our deep expertise in RNA biology/bioinformatics and neuro cell biology to probe the intricate regulation of each target and identify multiple upregulation opportunities. Our multi-year experience focussed on physiological upregulation has allowed us to develop bespoke assays and analytical techniques to screen for constructs that drive small increases in protein, which is a key challenge in this space. Our sole focus on neurodegeneration has allowed us to build deep expertise in the biology of neurons and our targets, and the best possible models for disease – critical in being able to de-risk and translate candidates to the clinic. Neurodegenerative disorders are chronic conditions that destroy parts of the nervous system over time, especially the brain. They result in progressive loss of cognitive and motor function and eventually, death. The most common neurodegenerative diseases include Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis (ALS), Motor neuron disease (MND), Huntington’s disease (HD), Spinal muscular atrophy (SMA), and Spinocerebellar ataxia (SCA). It is estimated that more than 50 million people worldwide are affected by neurodegenerative diseases and this number is increasing as overall life expectancy increases. Most of these conditions are much more likely to happen in people over 65, but some conditions like Huntington’s disease and ALS often appear much earlier.

Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are more than 10,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.

Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. Huma's technology has powered over 3,000 hospitals and clinics, with 500+ unique deployments across 70+ countries. The software has been used to engage and screen over 35 million individuals, with 1.8 million active users across its various products. The company is renowned for its role in major national healthcare projects worldwide, from the US and the UK to Germany, Greece, and Saudi Arabia, as well as working with most large pharma companies and CROs. The Huma Cloud Platform offers a technology infrastructure built on strong regulatory foundations to launch digital solutions for healthcare and research. Huma has achieved FDA 510(k) Class II, EU/MDR Class IIb, and Saudi FDA Class C regulatory clearance for its disease-agnostic flagship product, enabling rapid, code-free configuration with the ability to host AI/ML models.

hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

At ichorbio, we are passionate about animals and believe there is a better way to do in vivo research. For us, the most important consideration was that our antibodies for in vivo use have the lowest possible impact on the animals they are being used in. This is how our mission was born: to create the best antibodies for in vivo research. To achieve our mission, we have created products that have lower endotoxin, higher purity and lower aggregation than other antibodies currently available on the market. Our antibodies adhere to all the same criteria as many of the larger manufacturers from a quality perspective with the added benefit that you can feel confident that you are doing the best for your animals. Best selling antibodies: RMP1-14: https://ichor.bio/ich1132-compared-to-be0146 RMP1-14 LALAPG: https://ichor.bio/revolutionize-your-pd-1-research-with-rmp1-14-lalapg

IgniteData’s Archer technology is transforming the way hospitals and research sites transfer data for clinical trials. EHR-to-EDC data transfer provides fast, accurate patient data for clinical studies, significantly reducing the requirement for laborious data transcription and source data verification (SDV).

More than half of all clinical trials fail due to safety issues. Discovering drugs that show therapeutic potential is difficult, time-consuming, and expensive. But of those found, it is harder still to find those drugs which do not also have severe side effects and can pass through clinical trials. Most of these drugs are shelved and never reach patients. Safety issues are tough to fix without weakening the therapeutic effect, involving a mix of chemistry, biology, and knowledge of how humans will respond. Our proprietary AI model, SAFEPATH©, applies deep learning to our combined bioinformatics and cheminformatics datasets to solve drug safety issues. SAFEPATH© utilises the latest deep learning approaches to identify the mechanism of toxicity, predict its effects on the human body, and balance that with therapeutic effectiveness. We are building at speed a robust pipeline of matured assets. We look at historically failed clinical trials to identify the most promising targets as well as internal projects that were abandoned. By focusing on safety problems that occur in Preclinical, Phase 1, or Phase 2 trials, we are able to identify the most promising drugs therapeutically, turn them around quickly, and get them to patients faster than starting drug discovery from scratch. Our mission is to bring more treatments to patients, faster. Thousands of life-changing drugs fall at the last hurdle and never reach patients. We’re here to change that.

Ikarovec is a UK-based biotech gene therapy company with a focus in ophthalmology. Ikarovec was originally formed as a spin-out from the biotechnology company.

Iksuda Therapeutics is a biotechnology company focussed on the development of a new generation of antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of non-prodrug/prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform.

ILC Therapeutics (ILCT) is a Scottish-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of hybrid interferon drugs. The company is focused on modulating the Innate Immune System through the development of innovative therapies. ILC Therapeutics has raised significant funding to advance its lead interferon drug candidate and has announced its first international collaboration. The company is dedicated to revolutionizing the treatment of various diseases through its cutting-edge research and development efforts.

Immodulon Therapeutics Limited is a private, clinical-stage, immuno-oncology company dedicated to the development of novel, safe and effective treatments for cancer patients.

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company’s lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company’s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

Our vision is to provide the world with the next-generation of therapeutics for unmet medical needs and future threats.

IMU Biosciences is a UK-based techbio company that is revolutionizing immune powered precision medicine by mapping the immune system in unprecedented detail and scale. Their CytAtlas platform combines systems-level immunophenotyping with an AI platform to gain a new understanding of the immune system across health and disease.

Incanthera is a company with a current focus on a range of dermatological applications utilizing its unique formulation and delivery technologies.

We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.

Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, developing vaccines for the treatment of cancer.

IngenOx Therapeutics is a clinical-stage Oxford University spinout developing innovative drugs and vaccines aimed at re-invigorating the immune response against cold tumours.

Inspira Pharmaceuticals is a biotechnology company that specializes in preclinical research for diseases of the respiratory tract.

Intima Bioscience - A clinical stage gene and cell therapy company focused on curative intent in solid tumor cancer

IntraBio Ltd., which is a subsidiary of IntraBio Inc, is a private pharmaceutical company located in Oxford, United Kingdom, focusing on the testing and development of novel and repurposed drugs to treat rare neurodegenerative diseases including lysosomal storage disorders.

Intract Pharma is a biotechnology company innovating in the field of oral delivery of complex proteins such as monoclonal antibodies with a special focus on treatment of gastrointestinal and systemic immune-mediated inflammatory diseases. Intract is applying it’s Phloral™ and Soteria™ technology platform for precision delivery of proteins to the colon for local tissue and systemic immunomodulation. Our vision is to transform care for millions of patients suffering from chronic diseases by converting their potent injectable biologic medicines into safe, effective and convenient take-at-home pills.

InvenireX is a biotechnology company developing real-time, ultra-sensitive Nucleic-acid detection instrumentation powered by the latest AI neural networks.

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis. Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis. Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

iosBio believes that thermally stable, self-administered vaccines in capsule form are the future. Due to its OraPro™ platform, these are inexpensive to produce, developed in weeks and, following regulatory approval, can be distributed by mail. iosBio is using this approach to tackle the global COVID-19 pandemic, developing a capsule-based vaccine that could be easily distributed to millions across the globe. This comes after successfully working on an oral vaccine for the Zika virus. iosBio’s OraPro™ technology means these thermally stable viral vector-based vaccines can be delivered in capsule form to the GI tract. Viral vectors result in vaccines being developed cheaply and quickly, while administration via the gut elicits both mucosal and systemic immunity and allows for repeated administration of the same vector. In contrast, injected viral vector injections only target systemic immunity and can be used just once or twice as immunity to the vector itself is developed. This is made possible by iosBio’s THERM-SB technology. It allows for the storage of vaccines and viruses in powder form at ambient temperatures, eliminating the need for a cold chain to protect vaccines and other biotherapeutics when being delivered and in storage. Adopting this method can redefine the global approach to virus immunity. It will reduce our current reliance on often impractical mass vaccination programmes. These are based on injections that require huge numbers of healthcare professionals and expensive global cold-chains or even a -80⁰C cryo-chain. Through a combination of THERM-SB and OraPro™, iosBio is making its vision for an oral vaccine future a reality.

Isogenica is a bespoke biotech CRO specialised in solving antibody discovery and engineering challenges with small-format antibodies, particularly VHH single-domains. Sometimes known as nanobodies, sdAbs, or heavy-chain single domains, VHHs offer exceptional robustness, flexibility, and manufacturability - , accelerating antibody discovery and development. Their versatility makes them suitable for use in bi-specifics, ADCs, cell and gene therapies, targeted protein degraders, diagnostics and much more. We believe VHHs are the future of medicine - and our synthetic technology gives our VHH libraries the edge in accelerating your drug discovery and development programmes so you can focus on developing the ideas and technologies that could change lives. Offering the largest and most diverse synthetic VHH (nanobody) libraries available on the market, combined with our proprietary CIS display technology, means that VHH discovery with at Isogenica can interrogate up to 1000x more VHH antibody sequences than other display technologies. Our knowledge and experience of VHH, combined with our synthetic libraries’ size and diversity help deliver better antibodies faster, with higher affinity and broader IP coverage. Our in-house experts tailor each project to meet bespoke needs, allowing us to provide industry-disrupting antibody solutions to our partners in around half the time of a traditional animal immunisation campaign. Originally founded near Cambridge, UK over 25 years ago, Isogenica has evolved to become The VHH Company. As an established and trusted antibody partner, our track record of success includes dozens of lead panels including three clinical-stage assets. This bespoke and collaborative approach to antibody discovery extends to how we do business - working flexibly with different partners with uncompromising passion and dedication.

Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we're working at the cutting edge in the new era of ‘digital biology'. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.

Advancing medicine and human health by transforming data into clinically meaningful insights. IXICO is a premier neuroimaging provider helping biopharmaceutical companies maximize the value of their drug development pipelines by transforming data into clinically meaningful insights. Bringing together world-class therapeutic expertise, breakthrough analytics and operational excellence, IXICO is the proven partner of choice for imaging biomarker solutions in CNS clinical trials.

Juno Bio is studying the vaginal microbiome and its impact on women’s health and fertility. Women can purchase sampling kits, take a sample at home, and send it to Juno Bio where theywill analyze the DNA and return the results.

We are a clinical stage company developing novel therapeutics inspired by kanna, or Sceletium tortuosum. Kanna is a medicinal succulent traditionally used by the San hunter-gatherers of South Africa.

Kaerus is leveraging advances in human genetics to discover and develop targeted therapeutics for rare genetic syndromes of neurodevelopment.

Keapstone Therapeutics is a single asset biotech developing drugs that target the Nrf2 signalling pathway (KEAP1 inhibitors) for two devastating conditions – Parkinson’s and Motor Neuron Disease (MND) – which together affect more than 130,000 people in the UK. Keapstone was co-founded in February 2017 by the University of Sheffield, Parkinson’s UK and Dr Richard Mead and Prof Pamela Shaw of the Sheffield Institute for Translational Neuroscience (SITraN). The company combines world-leading research from the university with funding and expertise from Parkinson’s UK and consultants and discovery partners with extensive drug development expertise.

Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of genetically modified MSCs.

LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Their mission is to accelerate the discovery of next-generation therapeutic antibodies that have been designed for maximum potential. They are headquartered in London and their core technology platform, EVA™, enables the development of novel protein therapeutics.

Labocon is a renowned supplier of a wide range of Laboratory Equipment. The product range includes Analyzers, PCR products, General Laboratory Equipment like Mixers, Shakers, Temperature controlled Equipment, Balances & Microscopes etc. We provide as much information as possible about our products, and present them in simple and systematic way enabling the user to select the right product for their application conveniently. We make our client unperturbed by amending our products as per their needs. This is made achievable through our invincible staffs that constantly keep track of the research work going around the world. They are quite competent to add in the needs and refurbish the products. We are the one among the pinnacle to call upon for any requirement for your lab. Apart from this, our technical employees also work persistently on the automation of the products to help researchers in reaching their goal in a short time. We have laid our foundation over highest quality products with prompt & superior quality, after sales service and support.

Built by scientists, for scientists. Labstep is a digital research platform that allows researchers to collect, manage and share data securely in the cloud. With Labstep, lab management of reagents and equipment becomes easy and intuitive, allowing scientists to stay on top of their research. Our main objective is to allow scientists to spend more time researching and less time on data administration. Labstep is also tackling major issues faced by researchers around reproducibility of results. Over half of all scientific results published cannot be reproduced. To make data more reproducible, we allow real-time scientific data tracking for all researchers, thereby adding value to scientific output.

Lab Thread is a software tool for biologists that unites research projects, lab operations, and scientific data into one seamless platform to accelerate research breakthroughs.

Lancaster University is a collegiate public research university in Lancaster, Lancashire, England. The university was established by royal charter in 1964, one of several new universities created in the 1960s.

Laverock was founded around the core Gene Editing induced Gene Silencing Platform – a step-change in RNAi technology. We fundamentally believe it unlocks the development of next-generation therapeutics through its unique and differentiated properties. We are actively developing a pipeline of GEiGS enabled ex vivo cell therapies, as well in vivo therapeutic approaches.

Leaf Expression Systems is a translational R&D and contract manufacturing business focused on the plant expression of proteins, vaccines, and complex natural products. They use the power of plant-based expression and plant biotechnology to enable their partners to innovate and impact, helping to drive their productivity and create.

Based in Edinburgh, Scotland. Lentitek has pioneered the development of alternative approaches to lentiviral vector production based on novel promoter technology conceived by Dr Adam Inche. The Lentitek platform was developed to address key issues limiting progression of ATMP assets and is now enabling the use of retrovirus based vectors in new and previously unviable applications. Unique properties of the Lentitek platform can be leveraged to enable in-vivo CAR-T and armoured CAR applications in addition to addressing quality and yield inconsistencies within ex-vivo CAR-T manufacture. The Lentitek platform is accessed through a serviced CRO license model where Lentiteks’ renowned team of vector design specialists work with asset developers to integrate the Ltek solution and validate performance including transfer to chosen manufacturing partner.

Leucid is progressing novel CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers.

Levicept Ltd is a UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. LEVI-04 is currently in a phase II study in patients with osteoarthritis of the knee.

LEX Diagnostics is a privately held molecular diagnostics company developing products designed to enhance patient care by delivering clinical insights within minutes and at the time they are most valuable. Delivering a high-speed molecular test will redefine point-of-care diagnostics.

At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess.

Lightcast is developing a novel, droplet-based platform that provides a deeper understanding of cellular function. Compared to standard microfluidic methods, the Lightcast platform offers the ability to run a broader range of assays and to precisely control and track the number, occupancy, location, and movement of each droplet. The unprecedented scalability and flexibility of this approach will help advance translational and basic research as well as streamline development workflows for drugs, therapeutics, and applied biologics.

Linear Diagnostics Limited (LDL) is a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. The technology provides significant advantages over the current state of the art allowing a more rapid detection of multiple targets using a single simple reagent. Such a solution has applications in a number of high-value sectors including health, food, defence and security. LDL has also established development partnerships with a number of end users including clinical microbiology, food producers and defence medicine.

Founded in 2001, Linguamaticsusesnatural language processing (NLP)-based text mining for high-value knowledge discovery and decision support.

Based at the Babraham Research Campus in Cambridge, LinkGevity is a pioneering drug discovery company founded on ground-breaking research in longevity science. Our goal is to change the paradigm of ageing, paving the way for people to live healthier lives for longer.

Lirum Therapeutics is an innovative biopharmaceutical company focused on the treatment of debilitating diseases.

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. LivaNova is listed on the NASDAQ stock exchange under the ticker symbol "LIVN." LivaNova has approximately 2,900 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries. LivaNova is a worldwide leader in cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.

Living DNA is a high definition DNA testing that challenges the concept of race and tackles ideas of separation through our 'One Family, One World'​ education programmes. With 75% of clients living overseas we do this globally. Presenting self-truth and letting science talk helps people change their lives. Putting ancestry into context allows people to celebrate not only how unique they are but also understand how we are all connected going back through history.

Locate Bio bring together Programmed Drug Release and Instructive Tissue Scaffolds to develop the next generation of products with significant disruptive potential for musculoskeletal conditions.

LoQus23 Therapeutics is a company that targets DNA mismatch repair pathways to slow neurodegeneration in Huntington's Disease and other triplet repeat disorders. Recognizing the urgent need to find a treatment for patients with triplet repeat expansion diseases, LoQus23 Therapeutics was co-founded in 2019 by David.

Funded and run by scientists, Ludger Limited is a life science company specialized in glycobiology. We have been serving and collaborating with world-leading life science organizations for 23 years. We pride ourselves on the high quality and consistency of our products which are recognized by regulators and used world-wide in the development and quality control of new biopharmaceuticals and biosimilars. Since our technology originated at the University of Oxford, it has evolved into our three core areas: 1) Products for Glycan Analysis 2) Analytical & Consulting Services 3) Research & Development

We are a team based in London, that develops a platform to help assess people with Parkinson's disease better. Motor assessment in Parkinson's disease is plagued by issues of subjectivity and reproducibility – not to mention systematic biases such as rater drift. To counter this, we are developing a platform, called Kelvin, that can be used from any device (e.g. smartphones or tablets). Named after the famous physicist so beloved of precise measurement, the platform allows researchers to record, score, store and analyse video of Parkinson's patients during motor assessment. Once captured and organised, the platform uses a cutting-edge computer vision technique, called pose estimation, to objectively track the movement of the patients down to the fingertip level and deliver objective metrics of core symptoms, such as tremor and bradykinesia.

Macomics is a biotechnology company that focuses on developing precision medicines to modulate macrophages for the treatment of cancer.

An innovative C. elegans company, using our expertise and technology to provide quantified non-invasive assays of health outcomes for biotech, nutrition and other industries and research interests. - Prescreen compounds to reduce the number of experiments in mammals - Find effective and safe concentration ranges
 - Test mutants in signalling pathways - Screen libraries of mutants
 - Screen compound libraries 
 - Combine compounds and mutants
 - Adapt technology to address your questions We are a team of experts with a proven track record of: Designing customised C. elegans studies to provide answers to your specific ageing research questions Integrating C. elegans into drug discovery pipelines Working with innovative biotech and pharma companies Providing relevant, standardised, data rich assays

Magstim is a neurotechnology company that specializes in advanced brain stimulation and monitoring technologies. Founded in 1988 and headquartered in Whitland, Carmarthenshire, UK, Magstim is dedicated to advancing neurophysiology and neuromodulation. The company serves neuroscience researchers and clinicians globally, aiming to improve patient care for neurological and psychiatric disorders. Magstim develops and manufactures a range of precision neurotechnology tools. Their offerings include Transcranial Magnetic Stimulation (TMS) devices for non-invasive brain stimulation, high-density Electroencephalography (EEG) systems for monitoring brain activity, and transcranial Direct Current Stimulation (tDCS) devices for modulating neuronal activity. They also provide neurodiagnostic solutions, such as surgical nerve monitoring and intraoperative neurophysiology technologies. With a customer base that spans the globe, Magstim's products are utilized in research and treatment for conditions like depression, Parkinson’s disease, and epilepsy. Their tools have been referenced in over 20,000 clinical papers, highlighting their significant contribution to the field of brain science.

Malvern Panalytical is a global leader in the analytics of material and life sciences. We unleash the power of small things to make big things happen for our customers. Our vision is to make the world cleaner, healthier, and more productive. We partner with our customers to make their solutions possible through the power of precision measurements, our expertise, trusted data, and insights. Our people are partners in discovery. We collaborate with our customers and with each other to discover new possibilities and achieve breakthroughs. Our culture is a healthy, high-performance culture shaped by our values: Own it, Aim High and Be True. We’re committed to Net Zero in our own operations by 2030 and in our total value chain by 2040. With over 2300 employees across the globe, we are part of Spectris plc, the world-leading precision measurement group. Malvern Panalytical. We’re BIG on small™

Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

MDR specializes in cost effective high-quality biocompatibility testing, chemical characterization and safety assessment of medical devices. We are OECD-GLP and ISO17025 accredited laboratory and currently work with medical device manufacturers in more than 40 countries. Our reports are readily accepted for CE marking by notified bodies, FDA and other regulators globally. Please contact us at info@glrlabs.com'​

Medherant is a clinical-stage company developing innovative treatments using its novel transdermal drug delivery technology, the TEPI Patch, which is based on a proprietary adhesive developed by its scientists. The Company was founded by Professor David Haddleton and the University of Warwick in 2015 based on their world-leading expertise in bioadhesives and polymer chemistry. The adhesive has a high drug loading capacity, so a smaller quantity of adhesive is needed to deliver a therapeutic dose; the patch can therefore be thinner and more flexible. It also enables excipients, such as permeation enhancers, to be included in the adhesive so the release of the drug from the patch can be tailored to achieve the desired product profile. The adhesive also provides excellent adhesion, even in moist conditions. This means that the patch remains in contact with the skin throughout the dosing period, so the full dose is delivered. There is no leakage of adhesive from the patch so there is no unsightly black ring around its edge and no residue on the skin after removal. Medherant undertakes feasibility studies for other companies to investigate whether their drugs can be formulated for transdermal delivery using the TEPI technology. Medherant welcomes enquires from companies interested in licensing its products for commercialisation or undertaking feasibility studies.

Medicxi is an international investment firm focused on the life sciences sector. It wasestablished in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

MediSieve is a London biotech start-up developing Magnetic Haemofiltration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available for this product in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. Magnetic Haemofiltration has already been shown to rapidly, specifically, and effectively remove IL-6 from human plasma. The technology has completed pre-clinical validation, including animal studies, and is expected to start clinical studies in Q2 2022. MediSieve has raised £4M in equity funding and over £4M in non-dilutive grants. Seeking a further £8M at Series A to support pivotal clinical trials and regulatory approvals. EIS eligible. The company has been featured in numerous online and print media articles, including the Sunday Telegraph, Daily Mail, and Wired Magazine, and been winner or finalist in several start-up competitions such as Pitch@Palace, MassChallenge, OBN Awards, TCT Magazine Awards and CMS Healthcare Startup of the Year. Recently, our founder George Frodsham was awarded BBSRC Innovator of the Year and MIT Innovators Under 35.

Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused and capital efficient manner. Our journey began back in March 2015 fuelled by the desire to champion high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired three product candidates from Novartis in 2015 and one from AstraZeneca in 2017. Merging with OncoMed in 2019 strengthened our foundation, broadening our reach and adding cutting-edge oncology programs to our pipeline. The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options. Mereo’s agile approach is enabling us to move rigorously but quickly through trial programs. We have taken two therapies from in-licensing to pharma through to Phase 3 studies in under 5 years. Our portfolio covers potential therapies addressing critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and two oncology product candidates. Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across pharma and biotech. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We know what it takes to navigate reimbursement, which can be complex and have the expertise to drive excellence. Follow our updates on this extraordinary journey as we continue to collaborate with our stakeholders to forge new ways of doing things in rare disease.

Mesenbio is a preclinical biopharmaceutical business based at the University of York. Its Cell Line Extracellular Vesicle therapeutic is aimed at delivering next-generation medicine to patients.

Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career.

MetalloBio are developing two novel antimicrobial leads to combat multi-drug resistant Gram-negative bacteria.

At Metofico, we specialise in developing no-code data analysis software tailored specifically for life science research. We are dedicated to making powerful tools accessible to all researchers—regardless of coding expertise. Our mission is to enhance the efficiency, reliability, and reproducibility of data analysis, empowering scientists to focus on advancing scientific discoveries instead of spending time on tedious data processing. Our suite of tools—ranging from Fiber photometry analysis to AI-driven rodent tracking and automated behaviour quantification—is designed to streamline preclinical research. Additionally, we provide custom software and hardware solutions tailored to the unique needs of each research project. We uphold the highest scientific standards and continuously refine our offerings based on valuable feedback from the research community.

Metrion Biosciences is a specialist preclinical drug discovery CRO - your trusted partner for ion channel screening, cardiac safety screening and neuroscience assays. We provide our customers with a range of in vitro screening services, including cardiac safety (GLP hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, we have 250 years experience managing ion channel research programmes.

Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan and a joint venture in China. For more information, please visit www.mevion.com. About the MEVION S250 Series: The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The Series is comprised of: • MEVION S250, offering highly stable, next-generation volumetric delivery capabilities • MEVION S250i with HYPERSCAN technology, overcoming pencil beam scanning uncertainties by delivering robust Intensity Modulated Proton Therapy treatment at hyper-speed • MEVION S250mx, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and guarantee 100 percent facility uptime

MiAlgae aims to revolutionize the current livestock and pet feed industries by producing microalgae rich in polyunsaturated fatty acids (PUFAs) to offer as a replacement to fishmeal in feed. 🚫🐟 Feed suppliers are in need of this alternative to fishmeal due to declining wild fish stocks and rising demand for Omega-3s. MiAlgae has developed an environmentally beneficial, effective, and simple solution of producing microalgae which delivers the required nutrients to livestock and pets without the need for fish. ♻️ Our zero-waste solution recycles the nutritional co-products from whisky production to grow Omega-3 rich microalgae, returning clean water in the process. 🌍 Our mission is to create a product that will contribute substantially towards the sustainable production of livestock, a prerequisite to fulfilling the needs of the growing world population. 💡Please check us out and follow us on: -https://www.twitter.com/mialgae -https://www.instagram.com/mialgae/

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers

Micrographia Bio (MGB) has developed a new approach which uses spatial proteomics for stunningly sensitive and high-throughput assessment of the true molecular effects of drug candidates.

Microplate Dx Limited specialises in rapid antibiotic susceptibility testing diagnostics, enabling clinicians, at the point-of-care, to confidently select the best choice of antibiotic to treat a patient's infection in a matter of minutes, significantly quicker than the current gold standard technology which takes at least 2 days. Our award-wining, platform diagnostic test helps reduce the major global health threat of antimicrobial resistance and ultimately, saves lives.

Microsaic Systems Plc is a Healthcare Technology company that provides online, at-line, and front-line workflows for therapeutics, diagnostics, manufacturing, & environmental epidemiology using analytical instruments and mass spectrometry.

An R&D company focused on delivering innovative oncology and rare disease products to patients. Midatech has three platform technologies that are focused on improving bio-distribution and bio-delivery of medications in different ways – either via sustained delivery, targeted delivery, or direct delivery. These are: microspheres, saccaride nanoparticles, and gold nanoparticles.

EMD Millipore Corporation is a life sciences company that provides products and services for biotechnology, pharmaceuticals, and research and development.

We are pioneering the use of semiconductor technology for next-generation neural implants. Our mission is to provide the best possible outcomes for patients with neurological conditions by delivering the highest performance with the least invasive surgery. Our team brings together world-class experts in neuroscience, microtechnology, and implantable neural interfaces — augmented with medtech industry pedigree and clinical experience.

Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes of pH, seawater, or high concentrations of organic solvents. In addition, MIPs have a very long shelf life at room temperature which makes them ideal when the cold chain cannot be guaranteed. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. Using our proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP typically within 4-6 weeks of receiving the target.

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.

Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type. Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease. Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. Based in Cambridge, UK, the Company has raised over $40 million USD funding from Parkwalk, Ahren Innovation Capital, 24Haymarket, Trend Investment Group, Dr. Darrin M. Disley, OBE, Dr. Jonathan Milner and the University of Bristol Enterprise Fund III, as well as strategic investors; Astellas Venture Management.

Monument Therapeutics is an independent UK based biotechnology company formed as a spin-out from Cambridge Cognition. The company is focused on bringing precision medicine to neuroscience drug development, with a pipeline of proprietary biomarkers that allows precise selection of patients most likely to benefit from treatment. Monument Therapeutics is de-risking development by repurposing drugs with a favorable safety profile and proven mechanisms.

Mootral is a British biotech company operating at the intersection of two existential crises of our time - climate change and antimicrobial resistance. Our natural solutions are enabling a shift to new standards in agriculture by allowing farmers and processors to significantly reduce their methane footprint and improve animal health, thereby future-proofing our global food ecosystem. mootral.com

Morvus Technology Limited is a privately owned pharmaceutical company specialising in the discovery and development of novel drugs and diagnostics for the oncology sector. It has offices near Brecon, Wales. Morvus was formed in 2004 after the founders’ previous company, Enact Pharma plc, was acquired. Initially based on the Porton Down Science Park, near Salisbury, in 2007 the company relocated, with considerable assistance from the Welsh Government, to its present site. The company has a diverse portfolio of oncology therapeutics and diagnostics and its lead drug is a potent anti-tumour agent that displays minimal toxicity to normal tissues and is rendered harmless in the circulation. Morvus is developing this drug as a potential treatment for lung cancer using an inhalation route to deliver the drug to tumour sites. The drug is also being assessed as a potential agent to treat some skin cancers.

Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data points per patient accumulated from a wide spectrum of omics, rich clinical phenotyping and various tissue types collected over multiple time points. We use our proprietary MOHSAIC® platform to identify unique patient endotypes, re-position existing drug candidates and discover novel drug targets, leading to breakthrough precision therapeutics for the world’s largest patient population.

🔵 What do we do? Multus is reinventing growth media for cell culture in cultivated meat and life science. From growth factors to serum-free supplements, we partner with companies looking for media breakthroughs to help accelerate their progress and de-risk their supply chain. 🔵 How do we do it better? We use a groundbreaking combination of data science, high-throughput automation and ISO-certified manufacturing to develop ingredients and formulations that reduce costs, eliminate animal-sourced components and enable scale-up. 🔵 Why do we do it? Our Mission is to make cultivated meat the sustainable and affordable choice, for everyone. To get there, every cultivated meat company needs to achieve the following growth media milestones: 1️⃣ Reduced input costs 2️⃣ Use of food-grade, animal-free ingredients that are sustainably sourced and aligned with regulation 3️⃣ Optimised formulations to improve bioprocess performance 4️⃣ Established scalable feedstocks where supply meets future production plans Companies that choose Multus see us as an indispensable partner in their journey to scaling cultivated meat production.

Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East. Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain Management, Infectious Disease and Consumer Healthcare as well as other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do. We encourage our people to think differently and our inclusive culture of continuous learning and collaboration make Mundipharma a great place to work. For more information visit www.mundipharma.com See our community guidelines: mundipharma.com/social-media-community-guidelines

Myricx Bio is a biotech company headquartered in London, focused on discovering and developing a completely novel class of payloads for antibody drug conjugates (ADCs). They are focused on the discovery and development of a completely novel class of selective cytotoxic payloads for ADCs.

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world's leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients' products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry's premier, trusted partner for successful development and commercialization outcomes. Learn more: https://namsa.com/about/client-testimonials/

Nanogenics Ltd is a research-based biotechnology company, engages in the development of artificial viruses to deliver gene therapy.

NanoSyrinx is a cutting-edge synthetic biology company creating the next generation of targeted drug delivery systems to address challenges in the biologic delivery sector.

Nanothericsprovides products addressing the field of magnetic nanoparticle research and applications. In particular we aim to be the number one supplier of products for nanoparticle heating applications utilizing AC field and solenoid coil principles.

Nanovery is a biotechnology company founded in 2018 and based in Newcastle Helix, UK. The company specializes in nucleic acid nanorobotics, focusing on developing liquid nanorobot technology to advance nucleic acid research, particularly in RNA therapeutic analysis and biomarker quantification. Nanovery operates in the biotechnology sector, emphasizing research and development. The company's main offering is a proprietary platform that utilizes DNA nanorobotic sensors to quantify nucleic acid sequences in liquid samples. This platform simplifies the testing process by adding nanorobots to samples and measuring fluorescence to determine nucleic acid concentrations. Nanovery's technology supports RNA therapeutic development, biomarker analysis, and disease diagnostics, including early-stage detection. The integration of AI enhances data analysis and scalability, making the technology suitable for complex media. Nanovery has raised a total of $2.92 million in funding, with notable investors including Northstar Ventures and Innovate UK. The company aims to streamline testing protocols in biotech research, focusing on speed, cost-efficiency, and accuracy.

The National Health Service of the United Kingdom(NHS-UK)provides health care for all UK citizens based on their need for medical care rather than their ability to pay for it. The NHS was established in 1948 as one of the major social reforms following the Second World War and is funded by taxes.

NCIMB Ltd provides microbiology, analytical and biological material storage services. We work with companies from a diverse range of sectors including pharmaceutical. biotech, oil and gas, food and drink. Our microbiology services include GMP compliant identification of bacteria and fungi, whole genome sequencing and microbial community analysis, oilfield microbiology and qPCR. We are curators of the UK's National Collection of Industrial, Food and Marine Bacteria, and ship our strains around the globe.

Neobe Therapeutics is a biotechnology company based in Cambridge, UK, founded in 2021. The company focuses on developing engineered live biotherapeutics to improve the effectiveness of cancer immunotherapy. Neobe specializes in synthetic biology, creating programmable microbial therapies that target the tumor microenvironment in solid cancers. The company's innovative approach addresses immune exclusion in solid tumors, which affects a significant number of patients. Neobe engineers safe bacterial strains that remodel the tumor microenvironment, allowing immune cells to infiltrate and enhance the efficacy of existing immunotherapies. Their platform includes synthetic biosensors to create live biotherapeutic products that target tumors, disrupt immunosuppressive barriers, and ensure safety by confining activity to tumor sites. Neobe has two pre-clinical candidates aimed at high-need solid tumors, focusing on supporting existing immunotherapies rather than direct patient treatment. The company collaborates with academic leaders in synthetic biology and immunology and has received support from Cancer Research Horizons and investors like Pioneer Group and 2048 Ventures.

NeoPhore is a UK-based company founded in 2017, developing novel cancer therapies based on DNA-repair technology. The company targets the dynamics of cancer neoantigen evolution and aims to create effective medicines that will become a key part of the next-generation of cancer treatment.

NeRRe Therapeutics is developing orvepitant, a neurokinin (NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders. Having demonstrated proof of efficacy in patients with refractory or unexplained cough, NeRRe will now continue development in chronic cough caused by the rare and terminal lung disease idiopathic pulmonary fibrosis (IPF). A dominant feature of this severe progressive respiratory disease in a high proportion of patients is an uncontrolled and persistent cough which is disabling for these terminally ill patients. The cough is often refractory to medical therapy and there are no approved treatments. Idiopathic pulmonary fibrosis has been designated an orphan disease in both Europe and the USA

‘Neuro-Bio has discovered a novel 14 amino acid bioactive peptide (T14) derived from the C terminus of AChE. T14 is neurotoxic in the adult brain and published data shows it to be a potential key driver of neurodegeneration. This new distinct mechanism is being exploited by Neuro-Bio to discover first-in-class drugs to treat Alzheimer's disease and to develop a biomarker as a companion diagnostic'.

Neurochase was founded by a team of physician-scientists led by Professor Steven Gill in response to the growing need for CED consultancy services in the life science industry. Professor Gill is an Honorary Professor of Neurosurgery at the University of Bristol. He is a world leading expert in CED and has spent the past 20 years developing technology to facilitate highly accurate and safe targeting of deep brain structures using software and surgical robots. To learn more about Professor Gill, watch the following video interview where he discusses his clinical experience of intermittently delivering chemotherapy directly to paediatric brainstem tumours using his novel implantable neurosurgical device. Our Science: Convection Enhanced Delivery (CED) provides a method of achieving effective doses of therapeutics homogenously in targeted brain volumes that cannot be achieved safely with systemic or CSF delivery. Therapies are infused into the brain via micro-catheters and can be distributed in tightly controlled doses throughout the required treatment volume. The blood brain barrier now acts to retain the therapy in the brain targets thereby minimising systemic and off-target exposure. We believe that safe and scalable delivery of novel therapeutics by CED is achievable and will transform human health by unlocking treatments to previously untreatable neurological disorders.

Based in Belfast, Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world's greatest health challenges! Modius is the first product from Neurovalens which successfully launched in August 2017 on Indiegogo. Modius was designed to help improve the lives of people who struggle with their weight by using neuro-technology to help make weight loss easier.

We’re here to accelerate your therapy’s journey through the complexities of drug discovery and development. Putting innovation at the forefront of our capabilities, industry-leading experts help you confidently and proactively answer critical questions around the safety and efficacy of your product with our gold-standard in vitro models. By harnessing the power of predictive data, we navigate this crucial step efficiently and cost-effectively to maximise the potential of your therapy achieving clinical and market success. By combining our unique expertise with cutting-edge technologies, we’ve created predictive in vitro models that offer targeted solutions to your complex problems. Our tissue model platforms, including retina, kidney and lung, reliably and accurately mimic in vivo physiology to take the guesswork out of drug development – providing answers to your questions and a window into the future of your therapy. Our intelligent preclinical models provide the reliable data you need to identify, avoid and mitigate risks and failures. By better understanding how your therapy will interact in vivo, you can make assured decisions to reduce drug attrition and give your safe and efficacious asset the best chance of reaching patients. In a nutshell, we help you save money, save time and save lives by getting ahead of the game.

For those creating a more sustainable future with biotechnology, we use AI and computational modelling to help precision fermentation alt protein companies optimise their downstream processing, so they can de-risk their ventures, speed up R&D and reduce costs.

Low-cost, rapid whole genome sequencing is the future of infection control and clinical microbiology. Next Gen Diagnostics offers the low cost, high throughput, and automated sequencing and bioinformatics for a range of application, including tracking the transmission of disease in hospitals and pathogen surveillance for public health labs.

NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours. Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms.

NovalGen is an innovative immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. NovalGen is focused on the development of cutting-edge, proprietary treatments for patients with hematologic malignancies and solid tumors by developing therapeutics that treat cancer using our breakthrough technologies in Bispecific antibodies and beyond

NRG Therapeutics is passionate about bringing new medicines and hope to the growing number of people worldwide living with debilitating neurodegenerative diseases. The company is an innovative neuroscience company targeting mitochondrial dysfunction for the treatment of neurodegenerative diseases such as Parkinson's and ALS. NRG Therapeutics has been awarded a $500K grant from The Michael J. Fox Foundation to progress its Parkinson's program and has also announced a £16 million Series A to advance its mitochondrial therapeutics for Parkinson's and ALS.

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising our proprietary ProTide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

NunaBio is a privately-owned specialist DNA synthesis and development company. We are engaged in CRO (Contract Research Organizations) and CDMO (Contract Development and Manufacturing Organisation) activities. The company has built a solid reputation for its R&D flexibility and innovative approach to complex and challenging projects. NunaBio's core expertise is research and development into cell-free DNA synthesis, process optimisation, route design, scale-up and small-scale manufacture for clinical studies.

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

ŌGI Bio offers our customers in the microbiology sector an affordable route into the automation of routine microbial culturing. We do so through a unique modular, retrofittable device that allows customers to choose the specific functions they require for their processes as and when they identify them. This gives our customers a flexible base from which to accelerate their innovation by increasing their R&D throughput.

OKYO Pharma is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of inflammatory eye diseases and chronic pain. The company's main focus is the clinical development of OK-101 to treat dry eye disease (DED).

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Science Enterprises.

Omecu are the developers of a high performance genomics analysis platform providing secure access to large scale distributed datasets. Our team have spent over 10 years researching and developing in this area - building software solutions that allow researchers to quickly analyse large genomic datasets whilst ensure the security of the underlying data for the data holder. The company was formed in early 2021 to build on the research and development work from the university in this area.

Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based platform, delivers actionable insights into therapies to our pharmaceutical and biotech partners. Oncimmune's ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune is headquartered in the UK, with a discovery research centre in Dortmund, Germany and an office in Cambridge MA, USA.

🔒 Enabling a world of secure computing. Harnessing the power of light, we push the boundaries of what is possible in data security by bringing speed to always-encrypted data technology. Through optical computing, we accelerate Fully Homomorphic Encryption (FHE) beyond the capabilities of electrical computing, making secure data sharing and collaboration a reality for everyone, everywhere. To find out more, visit www.optalysys.com ✅ Join our unique community hub, the Innovation Lab, to develop your FHE skills with expert training, market insights, exclusive content and events. https://optalysys.com/register-for-innovation-lab/ 🔗 We are committed to building a home for exceptional talent. Keep an eye on our job vacancies https://optalysys.com/careers/ if you're interested in joining the team.

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company’s new Augmented Chemistry™ products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement your experience and skills. Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

When a five-year-old boy was blinded after a regular eye exam failed to spot a retinal detachment, his father made it his life's work to help eye care professionals by revolutionising retinal imaging. Optos was founded by Douglas Anderson with the goal to make a patient-friendly device to capture a digital ultra-widefield image of the retina. Today, millions of patients around the world have benefited from optomap® retinal imaging. You will find optomap systems in many independent High Street optometrists, as well as eye clinics at Great Ormond Street Hospital in London and Harvard Medical Center in Massachusetts. Our core products produce high resolution optomap images of 82% or 200◦ of the retina, something no other imaging device is capable of in a single comfortable capture. The most recent innovation from Optos integrates ultra-widefield retinal imaging and image-guided Optical Coherence Tomography (OCT). This combined device facilitates the early detection, management and effective treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy, and age-related macular degeneration. More than 1,000 published and ongoing clinical trials as well as thousands of case studies and testimonials show the long-term value of optomap imaging and OCT in diagnosis, treatment planning, and patient engagement. As a division of Nikon Co. Ltd, Japan since 2015, Optos is approaching its 30th anniversary and proud to be recognized as a leading provider of devices to eye care professionals to provide a more complete approach to patient care.

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. For more information, please visit www.orchard-tx.com.

"Living Organs For Life"​ Transforming transplantation with the OrganOx metra®. A transportable, automated ex vivo liver perfusion device. The core technology employed by the OrganOx metra® has been in development for over 15 years. During this time both of the founders (Professor Peter Friend and Professor Constantin Coussios) have driven the development of organ preservation and maintenance, formerly at the University of Cambridge and latterly at the University of Oxford. OrganOx Limited was founded in April 2008 as a spin-out from the University of Oxford. Conventional cold preservation involves storage of the liver at 4˚C, using a non-physiological perfusion solution that aims to minimise liver decay. By contrast, warm preservation seeks to re-create an environment that mimics the human body by continuously perfusing at physiological pressures and flows with oxygen-carrying red cells at 37˚C and providing nutrition. The liver is therefore functional during the preservation period, producing bile, metabolizing glucose and maintaining a physiological pH. This enables objective assessment of organ performance prior to transplant, extended preservation times, and the potential use of organs that are presently being discarded.

Ori Biotech is a London- and Philadelphia-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, lifesaving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.

Orion Pharma (UK) Ltd. is a wholly owned subsidiary of Orion Corporation, pharmaceutical company based in Finland. Our principal role is to represent Orion's pharmaceutical products in the UK across a range of therapy areas including Respiratory, Women’s Health and Neurological Disorders. In the spirit of the values which are common to all units and employees of the Group, we endeavour to provide innovative medicinal treatments and best quality service to patients, healthcare professionals and the community in the UK, the region we operationally cover. We are continuously developing new drugs and treatment methods. The core therapy areas of our pharmaceutical R&D are oncology and pain. We collaborate closely with healthcare professionals and leading global research institutions and pharmaceutical companies. www.orionpharma.co.uk July 2023/CORP-233(3)

Orla Protein Technologies is a leader in Life Science, specializing in recombinant protein design, engineering, and manufacture for surface applications.

Osler is a UK-based diagnostics company whose purpose is to enable anyone, anywhere, to access, understand, and act on their health, to live healthier, happier, and longer lives. Osler has developed the Osler Origin – a 'portable lab' that can provide lab-quality diagnostics to anyone, anywhere, at any time. The Osler Origin will offer a wide portfolio of diagnostic tests and serve all major healthcare settings, globally. Osler was formed out of the University of Oxford in 2017, following decades of research from the same department that invented the portable electrochemical blood glucose sensor. The Company is headquartered in Oxford, UK.

OSSIANIX, INC is a privately held pre clinical company that develops Biotherapeutic products using the highly versatile single domain VNAR antibody from the shark. The attractive biological and biophysical properties of the VNAR structure allows the rapid delivery of exquisitely high-affinity products to multiple target classes that have proven difficult or impossible by standard antibody approaches or alternative scaffolds. The company is headquartered in the University City Science Center in downtown Philadelphia and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts, UK. Ossianix was founded by Frank S Walsh, Corey Goodman and Lynn Rutkowski who have had distinguished careers in academia, Pharma and Biotech and bring a wealth of experience to the problem of delivering the next generation of Biologics products. The company started operations in 2012 with funding from Lundbeck Pharmaceuticals, BioAdvance and the ALS Association. Current programs focus on neurodegereration, neurooncology, ALS, pain and botulism.

Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.

Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.

Owlstone Medical is developing a breathalyzer for disease. With a goal of finding ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health, and other conditions. Our mission is to save 100,000 lives and $1.5B in healthcare costs by advancing early detection and precision medicine. Breath Biopsy® aims to develop a new diagnostic modality making it possible to discover novel non-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA® Breath Sampler ensures the reliable collection of breath samples. The volatile organic compounds (VOCs) present in breath are analyzed using state-of-the-art chemical analysis technologies. Our aim is to develop tools, potentially based on our proven microchip chemical sensor technology (FAIMS), to detect validated biomarkers of disease. The Breath Biopsy platform provides biomarker discovery and validation capabilities to support the development of applications in precision medicine for a wide range of other medical conditions. Highly sensitive and selective, our platform allows for early diagnosis when treatments are more effective and more lives can be saved. Owlstone Medical is involved in studies related to major and rapidly growing health concerns including lung cancer, asthma and liver disease. We are also participants in extensive partnerships focusing on multiple cancer types, pulmonary hypertension, mesothelioma, workplace exposures and much more. Our Breath Biopsy Products and Services are available to academic, clinical, and pharma research partners who want to develop breath-based diagnostics for their own applications. Our products and services are for research use only. Not for use in diagnostic procedures.

Oxford BioDynamics (OBD) is a global biotech company advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. OBD aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare with a portfolio of clinical tests and research tools based on its proprietary EpiSwitch® technology, uniquely capable of reproducibly translating 3D genome regulation for clinical application. The company's flagship product, EpiSwitch CiRT (Checkpoint inhibitor Response Test), is a first-of-its-kind smart blood test for cancer patients that provides guidance on navigating the toughest challenges of immunotherapy like treatment planning, pseudo-progression, and adverse events. The company is partnering with CLIA-certified commercial labs to deliver these important tests into the hands of physicians to meet demand and help patients as quickly as possible. OBD's 24,000 sq ft headquarters in Oxford, UK, houses offices and state-of-the-art laboratory facilities. OBD's commercial team has an office in Gaithersburg, MD, USA, and the company has an ISO-certified laboratory in Penang, Malaysia. OBD has participated in 40+ partnerships with pharma and leading institutions, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma. The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostics, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from 10,000+ samples in 30+ human diseases. OBD's proprietary EpiSwitch technology maps this 3D architecture at scale, identifying abnormal configurations that can be used to diagnose patients or predict how someone may respond to a disease or treatment. For more information, please visit oxfordbiodynamics.com.

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform is based on one of the world’s largest proprietary cancer membrane proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly qualified oncology targets, of which three programs are in clinical development in the USA and Europe. The company’s pipeline and development capabilities have been validated through multiple strategic partnerships, including with Boehringer Ingelheim, ImmunoGen and Kite Pharma as well as other world leaders in antibody development (such as Amgen, WuXi, Medarex (BMS), Alere (Abbott)).

Oxford Brain Diagnostics Ltd is rethinking how brain health is assessed and managed. Founded in neuropathological and neuroimaging expertise, the company's patented Cortical Disarray Measurement (CDM®) technology uses MRI brain scan data to support early and differential diagnosis, track progression, and predict the decline of neurodegenerative diseases. Oxford Brain Diagnostics is committed to assessing brain health based on changes in the cellular structure, supporting drug development, and helping clinicians around the world in their fight to defeat Alzheimer's and other neurodegenerative diseases.

Oxford Cancer Analytics Ltd (OXcan) is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.

Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We design innovative drugs with differentiated modes of action against cancer and other challenging diseases with high unmet medical need seeking superior patient outcomes. Based on the unique integration of our dual core competences in aminoacyl-tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. This distinctive drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates with highly innovative chemical scaffolds and modes of action.

As a leading global provider of diagnostic genomic solutions, our goal is to enable researchers and clinical decision makers to reach the right decisions for each patient, every time. The quality and innovation built into our products for NGS, arrays and FISH reflects our commitment to improving the future of genetic clinical care. We offer partnership and collaboration to our customers at every stage of their work.

Oxford Genetics is a synthetic biology company focused on developing novel technologies to overcome challenges associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.

Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world's first and only nanopore DNA and RNA sequencing platform. It's a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.

Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a bio-pharma company that was spun out from the University of Oxford’s Department of Oncology and is utilising the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for therapeutic vaccines and diagnostics in cancer and infectious diseases. The technology uses the novel, proprietary platform of ROPs to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other immune oncology (IO) agents. The company has extensive contacts and collaborations in China through Changzhou Bioscience Group (CBIG) that is using the ROP platform for diagnostics in both cancer and in infectious diseases. OVM is developing two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines will be tested as single agents and in combination with IO agents. OVM secured Series A investment from Cancer ROP, a leading South Korean healthcare institution, listed in KOSDAQ, and from existing shareholders in China in 2018. The company is currently seeking Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and also in combination.

Using advanced genetics and molecular biologyOxitechas developed a new and innovative solution to controlling the dangerous mosquito, Aedes aegypti.The Oxitec solution harnesses the natural instincts of male mosquitoes to find females in the wild. Oxitec has used genetic engineering to create ‘self-limiting’ male insects which seek out and mate with females. After an Oxitec male mosquito has successfully mated with a wild female, any offspring that result will not survive to adulthood, so the mosquito population declines.The Oxitec Control Programme is the system through which Oxitec mosquitoes are released and monitored over a predetermined and sustained period of time in an area with Aedes aegypti mosquitoes. By applying the Oxitec Control Programme to an area, the mosquito population in that area can be dramatically reduced or eliminated.Unlike conventional insecticides or pesticides, which kill insects indiscriminately, the Oxitec approach is targeted at a single species. This means that, as well as being more effective, it is much better for the environment than conventional tools.Oxitec is a subsidiary ofIntrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world’s biggest problems.

“One treatment a year. Life changing.” Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.

Our mission is to provide digital health technology to enhance clinical insights and endpoints. At P1vital, we bring clinical trials into the digital age, seamlessly integrating neuropsychology based technology in our eCOA platform. As well as traditional subjective assessments we have multiple validated objective measures that can be used to assess and track changes in behaviour and cognitive function. Our Facial Expression Recognition Task is recognized as a validated clinical assessment that has been implemented in more than 45 clinical trials worldwide. Our eCOA platform has proven success in managing the complex nature of CNS clinical trials across all phases of drug development and can be easily deployed in other therapeutic areas . If you are currently using different providers for each phase of your trial consider using P1vital as a one-stop solution. We would be delighted to show you how our eCOA platform can meet your needs across the whole clinical trial development process, saving you time, effort and reducing your costs. P1vital, the P1vital logo and all other P1vital product or service names are registered trade marks of P1vital Limited. © P1vital Limited and P1vital Products Limited. All rights reserved.

PartitionBio engages in technology platform that develops biomolecular tools for therapeutic and synthetic biology applications.

Pathios Therapeutics is a clinical-stage oncology and immunology company that targets the acid-sensing GPCR, GPR65. The company is focused on the development of first-in-class therapies for cancer.

PAA design and build laboratory automation systems, used within the fields of life and physical sciences, which allow integration with many different types of laboratory instruments to perform even the most complex experiments, interacting with numerous data sources. These systems are suited to the pharmaceutical, biotechnology and academic sectors. We provide a design and installation service to ensure you get the integrated lab automation solution you require to satisfy all aspects of your business.

Perceptive Inc. is a global technology-enabled service provider dedicated to the biopharmaceutical industry. Recently rebranded as "Perceptive," the company focuses on advancing life-changing treatments through innovative services and solutions. Perceptive offers a range of services, including Perceptive Discovery, which aids in preclinical and first-in-human imaging to identify promising compounds. The Perceptive eClinical division enhances patient and clinical supply management, featuring services like Randomization & Trial Supply Management and Interactive Response Technology. Additionally, Perceptive Imaging provides expertise in scientific, regulatory, and operational aspects to support efficient data collection in clinical trials. With a client base that includes many leading pharmaceutical and biotech companies, Perceptive operates globally, ensuring smooth execution of clinical trials across various regions. The company has played a significant role in supporting nearly 12,000 clinical research trials and over 800 approvals, particularly in oncology and neuroscience, while upholding values of customer-centricity, quality, and accountability.

Perspectum's imaging solutions are safe, fast, and can offer more comprehensive diagnostics. We help doctors understand complex data and help deliver precision care to more patients. We believe the voice of the patient matters and that each case is unique. Our goal is to enable health care providers to tailor precision medicine to the needs of the individual.

Welcome to the Phagenesis LinkedIn page!  At Phagenesis, we are dedicated to transforming the way dysphagia is treated. Dysphagia, or difficulty swallowing, can be a debilitating condition that affects millions of people worldwide. We believe that everyone deserves the ability to enjoy their meals and live their lives to the fullest, which is why we have developed the Phagenyx - a revolutionary product that uses Pharyngeal Electrical Stimulation (PES) to treat dysphagia.  The Phagenyx is a simple, non-invasive device that stimulates the nerves in the pharynx, helping patients regain control of their swallowing function. Our product has been rigorously tested in clinical trials and has been shown to significantly improve swallowing ability in patients with dysphagia.  As a company, we are committed to advancing the field of dysphagia care through innovative technology and evidence-based practices. We work closely with healthcare providers and patients to ensure that our product meets the highest standards of safety and efficacy.  We are proud to be changing the paradigm of dysphagia care, and we invite you to join us in our mission to improve the lives of millions of people around the world. Follow our page to stay up-to-date on the latest news and developments in dysphagia care, and to learn more about the Phagenyx and how it is helping patients overcome dysphagia.

Services

Embrace the next era of drug discovery with PhaSER's revolutionary 8HUM Mouse Model. Unlock significant time, resource, and cost savings, propelling the swift delivery of innovative drugs to market. Join us in reshaping the landscape of pharmaceutical advancement. PhaSER is transforming the landscape of drug discovery through the introduction of the 8HUM Mouse Model, a groundbreaking advancement in creating a more human-like model for drug development. In response to the limitations posed by traditional animal models in studying drug efficacy, we have developed a mouse model that addresses these challenges and closely replicates human drug metabolism. Phaser has a team of experts involved in drug discovery, development, and clinical trials. • We can supply 8HUM mice or subcellular fractions, e.g. microsomes • We can supply detailed information on the characteristics of the 8HUM model. • We can discuss drug development projects and how 8HUM can contribute to a program of work at all levels.

Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).

At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”.

PhoreMost is building a pipeline of novel drug discovery programmes aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalise drug discovery. Using this core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savings onto patients.

Physiomics specialises in integrating Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics with disease biology expertise to help biotech and pharma companies streamline drug development. Our goal is to extract actionable insights from all relevant data to de-risk critical decisions across discovery, preclinical, and clinical stages. This includes the optimal design of preclinical and clinical studies to give your drug the best chance of success. We leverage cutting-edge computational tools, custom-built models, and our proprietary Virtual Tumour technology to provide tailored solutions that accelerate development and optimise outcomes for our clients. With a track record of supporting over 100 commercial projects and modelling more than 125 targets and drugs, Physiomics has become a trusted partner to industry leaders such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.

PlaqueTec is pursuing a better understanding of the biological mechanisms of coronary artery disease (CAD) to advance the development of precision medicine. CAD, where atherosclerotic plaque build-up narrows or blocks the arteries that supply blood to the heart, is a leading cause of death globally. Current treatment approaches are one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression. A more detailed understanding of patient endotypes will support drug development by identifying new targets in specific patient groups, reducing clinical trial sizes and costs, and increasing success rates, ultimately improving outcomes for patients.

Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details.

Pneumagen is a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, as an intranasal drug for the prophylaxis of a wide range of viral respiratory tract infections (RTIs). Neumifil is a novel, engineered multivalent Carbohydrate Binding Module (mCBM), which is being developed for the prevention and treatment of Influenza Virus, Respiratory Syncytial Virus, Human Rhinovirus, and Coronavirus infections including SARS-CoV-2 virus. Neumifil acts by binding directly to sialic aid on host cells and preventing the entry of the viral pathogens into the host. Neumifil was generated using Pneumagen’s proprietary GlycoTarge™ technology that identifies novel mCBMs for further development. In addition to Neumifil, Pneumagen is harnessing its GlycoTarge™ platform to develop a pipeline of additional therapies targeting other infectious diseases. Pneumagen was established in 2016 as a spin-out from the University of St Andrews in Scotland giving Pneumagen access to world-class scientific expertise and capabilities in viral RTI’s specifically related to glycobiology.

PolyModels Hub kicked off in late 2022 with a mission: make modeling in Life Sciences easier for everyone and boost innovation. We started right here on Linkedin, building a community by sharing the latest research and open-source tools for life sciences. We are strong advocates for open-source modeling – it's akin to the transformation we saw in Software Dev and AI. That's why we recently introduced our open-source Hub, where you can sign up to discover, build and connect with the open-source community! Fast forward to 2024, and we decided to level up. We expanded PolyModels Hub to offer modeling services and products to the pharmaceutical industry. Our focus is on helping companies speed up their innovation in developing new drugs. We use the best digital design tools available, both open-source and proprietary, through our digital design approach and platform. The goal? Empower companies to launch medicines faster, save costs, and improve the quality of their products. And trust us, there's a lot more to come in our story!

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

Porvair Sciences, specialists in the manufacture of microplate products, serve Life Sciences, Biotechnology, R&D and Molecular Biology with microplate solutions for all applications, from sample preparation to high throughput screening via our global distributor network

Primerdesign is an innovative company focused on the design, manufacture, validation and supply of real-time PCR kits and reagents. Primerdesign is focused on developing improved solutions for real-time PCR. Founded in 2005 within Southampton University's School of Medicine, Primerdesign has unparalleled opportunities to access technology and clinically relevant material in pursuit of these goals. Primerdesign specialises in developing real-time PCR assays and reagents manufactured and validated to the very highest standard. Primerdesign developed the worlds first H1N1 swine flu detection kit in 2009 Primerdesign launched unique range of lyophilised ambient temperature stable qPCR reagents in 2012. Primerdesign was a central player in response to the horse meat contamination scandal in 2013. Primerdesign developed the Worlds first H7N9 bird flu detection kit for use in humans in response to the 2013 Chinese outbreak.

Procarta Biosystems Ltdaims to revolutionise the treatment of serious and life-threatening infection through the development of innovative new oligonucleotide-based antimicrobials.

ProImmune's mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen characterization platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. We are committed to helping you take your studies to success through product innovation, responsive service and focused application support, saving you time and money and reducing risk.

Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects.

ProteinLogic has developed ImmiPrint®, a novel diagnostic technology platform, based on the detection of non-obvious diagnostic patterns in soluble immune proteins in the blood and other body fluids through machine learning.

For when you need it all. We're here. We know scientists give it their all every day to reach their goals. Wherever your research takes you, Proteintech provides all of the antibodies you need to help you do that. All types and forms of antibodies are in stock for your experiment. We’ll be there for every step of your journey. With our GMP capabilities and recombinant custom antibody platform, we can provide the support to scale up from bench to clinic. Search the full catalog at ptglab.com.

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available. We have discovered and patented a large number of novel protein biomarkers for diagnosis, prognosis and treatment of key human diseases including neurodegenerative disorders, cancer, stroke etc. and provide protein biomarker services to pharmaceutical and diagnostics companies. We have wide experience across the life sciences sector working with many different human and animal sample types including blood plasma, CSF, solid tissues, cell culture material etc. As a reflection of the quality of our approach, the purpose built, state-of-the-art research facility in Frankfurt is certified to ISO 9001:2015 and GCLP

We profile the fundamental building blocks of life, providing cross-sectional snapshots, like a CT scan for your blood. We want to impact both primary and secondary care pathways. Our mission is to light the way in which cancer is diagnosed, treated and monitored. We aspire to deploy at population-level within the UK and globally.

Prozomix Limited is an enzyme discovery and manufacturing company located in Haltwhistle, Northumberland, United Kingdom.

At Psyomics, we’re helping people get the mental health support they need, sooner. Led by CEO Dr Melinda Rees, Psyomics aims to revolutionise the way we assess, diagnose, triage, and treat mental health. Cambridge University Biotech spinout turned Healthtech, Psyomics was founded by Professor Sabine Bahn, Laboratory Director at the Cambridge Centre for Neuropsychiatric Research. Following more than six years of research and development, our product — CENSEO — is a digital platform that significantly reduces clinical triage and assessment time through dynamic patient-reported information capture. CENSEO was commercially launched in late 2022 for the assessment and triage of 15+ mental health conditions, used by more than 6,500 patients to date.

PulmoBioMed commercialises state-of-the-art exhaled breath condensate & aerosol sampling technology as part of a platform for disease and environmental diagnostics. Our lead product, PBM-HALE is a passive fluid aerosol sampler engineered to segregate exhaled and environmental particles by size. Our technology solves key pains in avoiding sample contamination, preventing sample loss and generating highly reproducible data with digital molecular precision. The first of a series of products, PBM-HALE has demonstrated utility in biological agent capture, genomic/microbiomic analytics, and metabolomic profiling, through a one-stop solution. Our vision is to develop the first hand-held biomolecular analyser for medical, veterinary, well-being and environmental use. Our mission is to deliver molecular diagnostic-grade health data from your lips to your hand. PulmoBioMed Ltd. is a Northumbria University spinout company supported by the Northern Accelerator, iCURe, and InnovateUK.

Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.

The Quadram Institute is a British center for research and training in food science and health.

Quanta Dialysis Technologies is committed to making high-quality and cost-effective dialysis accessible to every patient in every setting with its Quanta Dialysis System - the first and only FDA-cleared device to perform IHD, SLED, and CRRT (CVVHD and SCUF) without any need for bags. As a compact device with performance comparable to larger traditional machines, the Quanta Dialysis System provides the clinical versatility needed to deliver kidney replacement therapy across multiple care settings. With an intuitive user interface and only once-weekly hot rinse requirement, the device is designed to be operated by a broad range of users to bring dialysis directly to patients. The Royal Academy of Engineering announced Quanta Dialysis Technologies as the recipient of the 2022 MacRobert Award (the UK’s longest running and most prestigious award for UK engineering innovation), joining the ranks of Rolls-Royce, Arup and Raspberry Pi.

An exciting new cell therapy immunology biotech committed to transforming patient's lives in solid organ transplantation and auto-immune conditions. Our company is growing and we are exciting about the future! Our vision is to become a world leader in new cell therapy and the people are at the heart of what we do. We treat our people with respect, working collaboratively across the business, taking ownership and accountability for the outcomes and results we delivery. Most of all we work with integrity to innovate and bring the best version of ourselves to the job every day.

Provide formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry.

Rayner manufactured the world's first IOL in 1949, and has remained at the forefront of innovation for over 70 years, focused on providing you and your patients with the best IOLs and ophthalmic solutions - always driven by science to improve patient outcomes and safety. Rayner is the only manufacturer of IOLs in the UK, with its state-of-the-art manufacturing plant and Global Headquarters on the South Coast of England. Rayner is a fast-paced and growing business with 500+ employees worldwide.

ReadyGo™ is a technology company dedicated to simplifying diagnostic testing by offering devices and assays that make testing more accessible and decentralised. These devices streamline sample collection and seamlessly integrate with existing tests on the market. ReadyGo also designs assays and diagnostic tests tailored for use on both our innovative diagnostic platforms and other laboratory-based systems. Our products are well-suited for human healthcare and can also be applied in agricultural and veterinary diagnostics and in forensic settings.

World-leading design and animation studio for Bio/Med/Tech. We help young as well as established companies convey the excitement and innovation of their research, technology and products to a wider audience - be it clients, investors or patients.

Redx Pharma is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases Our team of scientists are based at our labs at Alderley Park, Cheshire, the UK's largest single site life science campus. The team is made up of world class medicinal chemistry, biology and clinical capability with deep-rooted biotech and large pharma experience. Redx's lead asset, the selective ROCK2 inhibitor, zelasudil (RXC007), is in development for idiopathic pulmonary fibrosis and commenced a Phase 2 clinical trial in Q4 2022. Redx's second ROCK inhibitor candidate, RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, commenced a Phase 1 clinical trial in Q1 2024. The Company's lead oncology product candidate, the Porcupine inhibitor, zamaporvint (RXC004), commenced a Phase 2 programme in November 2021. The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. Read more about our company at https://www.redxpharma.com/about-us/ If you're interested in joining us, please visit https://www.redxpharma.com to see what job vacancies we currently have.

Polypeptides from Colostrum

We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.

We are a global, clinical stage pharmaceutical company with a mission to develop and commercialise clinically meaningful, novel therapeutics that will bring life-enhancing benefits to children across the world. Our first development program focuses on Hu14.18, a humanised anti-GD2 monoclonal antibody, licensed from St. Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. A novel key Phase II trial incorporated the addition of Hu14.18 antibody to standard induction chemotherapy and demonstrated outstanding outcomes in patients with newly diagnosed high-risk neuroblastoma, with a 3-year event-free (EFS) and overall survival (OS) of 73.7% and 86.0% respectively. Renaissance Pharma Ltd is led by an Executive Team with extensive experience in the development, approval and commercialisation of oncology and rare disease products. We invite industry manufacturers, formulators, researchers and investors to collaborate with us. Together we can build new partnerships to improve patients' lives. To discuss partnership opportunities, please contact info@renaissancepharma.co.uk We invite industry manufacturers, formulators, researchers & investors to collaborate with us. Together we can build new partnerships to improve patients' lives.

Our focus at ReNeuron is on our CustomEx exosome technology platform, producing exosomes with unique tissue targeting tropisms to deliver a payload of choice to a preferred cell type. Our mission is to partner and develop novel exosome therapeutics for diseases with significant unmet needs.

Resolution Therapeutics is a biotechnology company developing macrophage cell therapy to treat inflammatory organ disease. The company was founded following a productive collaboration between Edinburgh’s Centre for Regenerative Medicine, the Scottish National Blood Transfusion Service, and Syncona Investment Management Limited. The company is based in the Centre for Regenerative Medicine on the Edinburgh Royal Infirmary Campus, and is backed by Syncona. Our initial focus is in chronic liver disease. It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, only supportive therapies are currently available. For patients with end-stage liver disease (cirrhosis) the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors. At Resolution Therapeutics, we are developing a macrophage cell therapy product to treat patients at risk of liver decompensation, thus helping them avoid the need for a liver transplant.

Re-Vana Therapeutics is a venture-backed, pioneering therapeutics and ocular drug delivery company developing innovative sustained-release biologics to treat serious retinal diseases. The company’s proprietary photo-crosslinked, biodegradable platform technologies, EyeLief®, EyeLief SD™ and OcuLief®, enable custom delivery of a wide range of therapeutic molecules. Numerous platform capabilities create a therapeutic continuum to expand treatment opportunities through both internal development and external, strategic collaborations. Re-Vana envisions a new industry standard for sustained delivery of biologics to the retina, creating transformative and differentiated treatments for physicians and significantly reducing patient treatment burden.

RevoluGen is a privately held scientific research and development company commercialising molecular tools with a specific focus on rapidly extracting long and pure DNA fragments from cells. RevoluGen's Nucleic Acid Isolation and Purification (NAIP) products have broad application across short- and long-read DNA sequencing, including in population genomics, epidemiological mutation screening and antibiotic microbial resistance gene monitoring. Fire Monkey significantly improves sequencing results by extracting long-fragment DNA with a simultaneous size selection function built into the protocol that minimises the small-fragment DNA contamination. Used independently, the size selection protocol of Fire Flower can improve the molecular ratio of any extraction kit and is compatible with all sequencing technologies. The Company headquarters, R&D, manufacturing and direct customer sales and support are based in the UK. RevoluGen serves customers worldwide and has secured agreements with world-leading molecular biology tools companies including Merck KGaA (sales), Cytiva (manufacturing), Tecan (automation) and A4P (logistics). Watch our film https://vimeo.com/465291714 and animation https://lnkd.in/dHy3E3s

Rinri Therapeutics is a private biotechnology company developing first-in-class cell therapies to restore hearing. Hearing loss affects 350m people in the world; 90% caused by sensorineural hearing loss (SNHL). There are currently no disease-modifying therapeutics for SNHL patients. Rinri's pioneering technology seeks to reverse SNHL through the regeneration of the damaged sensory cells in the inner ear, the cochlea. Rinri is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield.

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines. Roquefort Therapeutics’ portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of: 1. Midkine antibodies with significant in vivo efficacy and toxicology studies; 2. Midkine RNA therapeutics with novel anti-cancer gene editing action; 3. MK cell therapy with direct and NK-mediated anti-cancer action; and 4. siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.

RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. Discover more about our services at www.roslinct.com.

RQ Biotechnology is making instant immunity a reality for vulnerable people. As the leading passive immunization discovery company, we partner with pharmaceutical companies to develop our antibodies into protect against infectious diseases where vaccines cannot. RQ Bio is dedicated to developing medicines based on potent broad-spectrum mAbs to provide instant and long-lasting protection for vulnerable people at risk of severe disease or death from current and future viral infections.

Prevent target safety failures with unique data insights and cutting-edge approaches. ‍ Better prediction of drug safety could help patients and prevent hugely costly trial failures. Our advanced workflows assess clinical side effects and predict potential risks for drugs in development using a suite of data modalities. Empower your drug development process with our state-of-the-art solutions. Build trust with industry-leading validation across several proof points. Gain deeper insights into target safety, minimize risks, and optimize assay validation strategies.

Salient Bio is an innovative, fast-growing biotech start-up combining synthetic biology and robotics to build digital-first laboratories that make diagnostic testing available to all. We pride ourselves on the ingenuity of our automation, excellent customer service and agile approach to the market and our customers' needs. We believe in the power of preventive healthcare, and that access to diagnostic testing - both conventional and cutting edge - should be available to everyone. This is our North Star, and everything we develop is in service of our mission to deliver a world class diagnostics service and experience. We are based in central London, where we've built a state-of-the-art laboratory offering a wide range of diagnostic testing, both, routine and specialised, as well as operating an R&D microbiome laboratory undertaking cutting edge research. This represents the start of our journey to transform the delivery of mass-scale diagnostics to communities around the world. Contact us to learn more: info@salient.bio.

Built for precision, designed for patients. Sania [sah-nee-ah] is a London based biotech company building therapeutics that transform the lives of people with diseases of dysfunctional neural circuits.

Sano combines genetic testing, recruitment, and long-term engagement in one platform, accelerating enrollment and simplifying operations for precision medicine teams driving breakthroughs for patients.

All the health information we need is within us. Just below the skin. SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless, real-time and affordable way.

Scancell is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. We have developed a pipeline of ‘off-the-shelf’ vaccines which induce immune responses and highly tumour specific monoclonal antibodies that redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

A revenue generating producer of high value, natural biochemicals Creator of a flexible, scalable platform Innovator of versatile synthetic biology platforms Commercially selling ScotBio Blue, a natural blue extract from spirulina used as an internationally approved food colourant

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities. 14C Custom Radiolabelling for pre-clinical ADME studies 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate) GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance Stable Labelling (13C, 2H, 15N) Internal Standards, Metabolites and Impurities Stable Labelling 13C 2H 15N GLP Analysis Certification and Problem Solving including GLP NMR www.selcia.com contact@selcia.com

SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells. At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.

Sense is transforming healthcare by redefining diagnostics. Founded in 2014, we strive to improve lives by bringing powerful tools for fast, accurate, and accessible diagnostics to all. We’re focused on creating a portfolio of unconstrained, instrument-free molecular diagnostic technologies. Our Veros™ platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. We’re developing technologies that combine the power of laboratory tests with the simplicity and ease of use of products because we believe that if you can test anywhere, you can change everything.* *Professional use, patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST. This breakthrough technology is currently being applied to the world’s most prevalent diseases and infections where earlier and more prevalent diagnoses can make the biggest impact. Founded with the goal of developing PCR accurate point-of-care diagnostics for the world’s most deadly diseases, Senzo Health builds high sensitivity, low-cost, real-time testing technologies. PRICE Laboratory-based diagnostics are expensive, to the individual, the insurer, and the system. By lowering the price of modern diagnostics, we dramatically increase their use and value within healthcare. ACCURACY The Senzo Amplified Lateral Flow test is PCR-accurate. This means that for the first time we can bring testing for a range of new infections and diseases out of the laboratory and closer to the patient enabling a revolution in both diagnostics and treatments. SIMPLICITY Current diagnostics are too complex. From appointments to samples to laboratories to results. By simplifying diagnostics and bringing accurate and real-time testing to the patient, we can save money, save resources and save lives. SPEED Testing is about accurate results. The faster we can return a diagnosis, the sooner we can begin a treatment. Currently, patients and health care professionals often wait days for results. Real-time testing changes this forever, removing the gaps between consultation, testing, data and treatment. ACCESSIBILITY Accurate diagnostics today remain unevenly distributed. The only way to bring testing to patients in lower-income areas is to replace the complex central laboratory model with an affordable point-of-care diagnostics system without sacrificing accuracy.

Sequirus is one the largest cell-based influenza vaccine producer in the world. The company also makes antivenoms, and Q fever vaccine.

great people, great work, real results Sequani's heritage spans more than 50 years when a company called Toxicol Laboratories opened for business in London. A little while later the company moved to the current site in Ledbury's Bromyard Road. Toxicol Laboratories then joined with Quintiles and the foundations were laid for the company as it is today. The name Sequani dates back to the year 2000 when, after seven years of association with Quintiles, the company changed ownership under a new identity. The name Sequani comes from a Celtic tribe made famous for harrying invading Romans during their suppression of Gaul. We feel the name is apt as we too give the big boys a run for their money! We achieve this by working closely with you to deliver flexible and fast solutions that help keep your development programmes on schedule. Our customer feedback consistently shows that the service and commitment our clients enjoy is the most personal and direct in the business. But we take none of this for granted. Our focus is continuous improvement so that we carry on growing through the repeat business of loyal customers as well as attracting business from new clients.

Sequential Skin is a Singapore-based healthcare organization that provides services such as genetics and microbiome research for the treatment of skin diseases.

Seven Bridges is the industry-leading unified bioinformatics solutions company accelerating precision medicine by enabling the understanding of biomedical data. Our platform, analytic tools, and services expertise are driving discovery and drug development at the world’s leading academic, biotechnology, government, hospitals, and pharmaceutical entities. Through our collaboration with the largest genomics projects, we connect the world’s biomedical information to enable the most efficient analysis at scale.

Severn Biotech is a microbiology company that specializes in laboratory services and biotechnology.

Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high throughput and high accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes the norm.

Singer Instruments make laboratory automation to accelerate research for biologists who want to make the world a better place. Singer Instruments was established in 1934 and has a long-standing track record developing and manufacturing mechatronic workstations and laboratory automation robotics. Our world-leading, specialist products are used to facilitate and accelerate genetic and genomic research around the world. We supply public and private research institutions in multiple facets of biological sciences including Genetics, Neuroscience, Systems Biology, Cancer Biology, Biofuel Engineering and microbiology. Our headquarters, on the edge of Exmoor National Park in Somerset, England, is a state-of-the-art factory with full, virtual prototyping facilities, precision CNC manufacture and robotic coordinate measurement for quality control. We design, manufacture, program, assemble and QC all of our core products on site. As an employee-owned company, Singer puts their people first. Singer Instruments are very proud to have won the Somerset Business Awards Employer of the Year; By supporting our teams and investing in our people, we get the best results for our customers. Having worked alongside and added value to laboratory research for over 40 years, we are a truly integrated and respected member of the genetics research community. Our tag line ‘a responsibility to science’, acts as a continual reminder for us to do our utmost to support, develop new technology, and add as much value as possible to the science and the scientific community we serve. Should you have any feedback, suggestions or collaborative opportunities that may help accelerate scientific research, we would be delighted to hear from you.

Sireau Labs is a new biotech based in Cambridge, UK, that is using mRNA technology to develop ground-breaking treatments for rare genetic diseases. Sireau Labs is engineering solutions for rare diseases with science that is at the forefront of precision medicine. We are in a daily race to save lives stolen or impacted by rare disease.

We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and are maximizing the potential of our technology through research partnerships. Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, we have fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.

Develop safe and effective drug delivery systems for cell andgene therapeutics.

SkinBioTherapeutics is a life science company focused on skin health. SkinBioTherapeutics is targeting five specific healthcare sectors: Cosmetic, Food Supplements, Medical Devices, Hospital and Domestic Surface Hygiene and Pharmaceuticals.

Chronic wounds affect ~100m people around the world, impacting quality of life & placing a huge burden on health systems. Despite the many innovations in wound care over the years, chronic wound healing rates have barely improved. Change is needed – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations in chronic wound care. SolasCure is at the forefront of addressing this demand, aiming to shift the current treatment paradigm with a high impact therapeutic approach to debridement, with the goal of enabling dramatic improvements in healing rates and patients’ quality of life. Aurase Wound Gel aims to address the huge unmet need for easy & effective debridement to return wounds to healing. It combines the enzyme Tarumase with hydrogel to debride wounds, reduce biofilm & promote healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation. After successful Phase IIa trials, SolasCure is preparing for the next phase of clinical development to bring Aurase Wound Gel one step closer to improving the lives of millions of patients suffering from chronic wounds. For more information, you can find our peer-reviewed publications here: Clinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14805 Preclinical: https://onlinelibrary.wiley.com/doi/10.1111/iwj.14079 The importance of our innovative technology has been widely recognised: - Innovate UK Global Incubator Programme (Innovate UK, the UK’s Innovation Agency), Texas Medical Center, 2024 - Biomedical Catalyst Grant (Innovate UK, the UK’s Innovation Agency), 2024 - EIC Accelerator Grant (European Innovation Council), 2023 - Life Sciences Innovator (UK Department for Trade and Business), 2023 - EIT Health Catapult, Biotech Category (European Institute of Innovation & Technology), 2022 - Winner 2019 URGO Mentorship Programme. Visit us at www.solascure.com

Sonrai is the only multi-omic cloud AI solution designed for precision medicine. Our experts have developed a Bioinformatics Cloud product explicitly designed to work with precision medicine data, alleviate pain points, and help succeed from early discovery through to clinical phases and beyond.

Sortera Bio is a biotechnology company based in Cambridge, UK, focused on AI-driven biologics discovery. Incorporated in August 2023, it emerged from the MRC Laboratory of Molecular Biology, utilizing intellectual property developed through collaborations, including a partnership with AstraZeneca. The company specializes in its Deep Screening platform, which generates extensive sequence-function datasets in single experiments. This technology allows for efficient identification of therapeutic candidates with drug-like properties. Sortera combines experimental data with generative AI to enhance biologics development, ensuring robust training datasets and large-scale validation. The company collaborates with pharmaceutical leaders to address complex challenges in biologics, leveraging its expertise in protein engineering and synthetic biology. With a revenue range of £11M–£100M and a team of 11–50 employees, Sortera Bio is positioned at the forefront of machine learning and high-throughput drug discovery.

Source BioScience, comprised of Source LDPath and Source Genomics, provides industry-leading laboratory services in Genomics and Histopathology, partnering with biotechnology, pharmaceutical, healthcare and academia. Source LDPath provides an end-to-end clinical diagnostic service, from histopathology, including digital pathology and AI, through to molecular diagnostic services. Source LDPath already supports over 85 NHS Trusts and a comprehensive network of Private Healthcare clinics to expand their diagnostic capabilities, ensuring diagnostic results are delivered within clinically actionable timeframes. Source LDPath brings pioneering expertise in digital pathology and AI implementation, helping NHS pathology departments digitise their workflows for streamlined operations and greater diagnostic reporting capacity, tailoring integration touchpoints to the specific requirements of the Hospital or Trust. • Cellular and digital pathology wet laboratory processing • Reporting - access a pool of over 200 specialist consultant pathologists • MDM and Second Opinions • Digital Implementation Support with AI integration • Connectivity and LIMS integration with Source HIVE™ Source Genomics provides a broad portfolio of multi-omic services, delivering high-quality data in Genomics, Spatial Transcriptomics, Proteomics and Epigenomics. Market-leaders in Sanger Sequencing and Next-Generation Sequencing Services, Source Genomics delivers bespoke laboratory expertise to excel your project at rapid turnaround times. • Sanger Sequencing • NGS - WGS, WES, RNA-seq • Oxford Nanopore Sequencing • Olink proteomics • Optical Genome Mapping • 10x Genomics Visium • Bioinformatics • And more Contact us today at enquiries@sourcebioscience.com.

Spirea Limited is a Cambridge-based company created to advance a new generation of antibody-targeted cancer treatments with significantly better efficacy and safety profiles. Spirea will use its innovative technology to enable a pipeline of superior and differentiated antibody drug conjugates for the treatment of a range of solid tumours.

SPOREGEN LIMITED is a biotechnology company based at The London BioScience Innovation Centre (LBIC) in London. SPOREGEN is focused on four areas. 1. Clostridium difficile: we have developed a unique prophylactic and therapeutic approach for C. difficile infection. 2. Probiotics: we identify and develop Bacillus, heat stable, spore probiotic formulations. This includes progression to GRAS status and a number of these have now been licenced including HU58 and HU36. 3. Prophylactic approaches to COVID-19 including SPOR-COV, a unique mucosal immune modulator, and SPORCOVAX, a mucosal vaccine. 4. Contracts: focusing primarily on in vivo evaluations of C. difficile interventions.

SPT Labtech designs and makes products that transform the way scientists work. For over two decades, our expert scientists, engineers, and business innovators have created innovative solutions for liquid handling, sample preparation and management that help accelerate research and make a real difference to human health. We work collaboratively with our customers, building trusted relationships that enable us to deliver exceptional, personalized experiences designed for real world challenges in the lab. • Whether you operate on a nanolitre, microlitre or millilitre scale, our liquid handling solutions allow you to handle samples and reagents with accuracy and speed, across genomics, drug discovery and structural biology applications (firefly®, mosquito®, dragonfly®, apricot®) • Stay organized in the lab while saving valuable time and resources with our suite of automated sample management systems, including -80°C to ambient storage (comPOUND®, comPACT®, arktic®) and essential day-to-day tube management (BioMicroLab range, lab2lab) • Optimized cryo-EM sample and grid preparation is easy with chameleon® and Quantifoil, delivering consistently high-quality images and data.

SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year.

Start Codon leverages the unique resources of the Cambridge Cluster to identify, seed-fund and drive the success of truly disruptive healthcare start-ups.

Stratech Scientific Ltd. is a UK-based distributor of life science research tools, established in 1983 by Sue Hallett. The company specializes in overcoming logistical challenges related to temperature-sensitive biological products. With a revenue of $8.5 million and a team of approximately 20 employees, Stratech has built a reputation for reliability and customer-centric services, offering a money-back guarantee on all products. Stratech distributes over 90,000 life science research tools globally, including antibodies, molecular biology tools, sample preparation reagents, and specialized biochemicals. The company serves a diverse customer base, including academic, pharmaceutical, and biotechnology research laboratories. It has longstanding relationships with institutions like the John Innes Centre and supports manufacturers in entering European markets. Stratech is known for its expertise in cold-chain distribution and provides technical support tailored to various research applications.

Strides Pharma Science is a global pharma company headquartered in Bengaluru and a footprint across 100 countries. We operate two business verticals, Regulated Markets and Emerging Markets. Our manufacturing footprint covers 8 manufacturing facilities in 4 continents, including 5 US FDA approved facilities and a dedicated R&D facility in India with global filing capabilities. Our core competence is in the development and manufacture of wide range of niche and technically complex pharmaceutical products. We are also among the world's largest soft gelatin capsule manufacturers. For more details, please visit www.strides.com

Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation, with over 1000 staff from 53 nationalities, including 900 scientists working on drug discovery programmes. Founded in 2004, we have delivered over 40 pre-clinical compounds, 21 clinical compounds, and our scientists are named on over 170 patent applications. We partner with global pharma, biotech, and NFP organizations, providing integrated drug discovery services from target identification through to candidate nomination. Our co-located teams are experts in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management, with a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases and fibrotic diseases.

Symbiosis Pharmaceutical Services is a contract manufacturing organisation (CMO) that specialises in the GMP manufacture and sterile fill/finish of vials for clinical trials and low-volume commercial supply. Regulatory compliance, technical capability and operational flexibility are at its core. Manufacturing takes place in a purpose-built MHRA-licensed and FDA approved facility, enabling the CMO to handle products that require aseptic liquid filling and lyophilisation for a range of complex biologics, viral vectors for use in gene therapies and small molecule drugs. Offering fast access to manufacturing slots and accelerated release of drug product, Symbiosis is primed to meet demand for small-scale, fast-turnaround drug product manufacturing, while maintaining regulatory compliance to the highest standards. Symbiosis specialises in the sterile fill/finish of biologic and small molecule products into vials, which are either liquid or lyophilised formulations. Capabilities include the ability to handle and fill antibodies, proteins, peptides, nucleic acids, cytotoxic, cytostatic and highly potent APIs including ADCs along with conventional small molecules. Symbiosis saves our clients invaluable development time. With short lead times to manufacture and faster release of sterile drug product, we get you into phase I/II quickly. Our focus is service excellence through flexibility, responsiveness and timeliness. If you need a drug filled aseptically, come and speak with Symbiosis...we will exceed your expectations.

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is currently running a Phase II trial evaluating SNG001 in COPD patients and announced on 18 March 2020 a Phase II trial with SNG001 in COVID-19 patients to potentially assist with the global outbreak.

SynaptixBio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases.    SynaptixBio's mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. Using a breadth of platforms including antisense oligonucleotide (ASO)-based technology, we can silence the expression of the toxic gene to reverse disease progression. This approach will create life saving treatments for severe genetic diseases that affect the central nervous system.

SynbiCITE is the UK's national centre for the commercialisation of synthetic biology. The prime objective of SynbiCITE is to accelerate and promote the commercial exploitation of synthetic biology research and technology. SynbiCITE's role as nucleating point for this rapidly emerging industry is designed in time to deliver sustained and substantial benefits to the UK economy. SynbiCITE is a unique collaboration of UK's leading academic institutions and industrial partners, ranging from start-ups to large multinational companies, and supporting organizations including the Northern Ireland, Scottish and Welsh Regional Governments and the Greater London Authority. SynbiCITE is one of seven IKCs set up to nucleate new industries, by closing the gap between scientific research and its commercial exploitation. IKCs are a key component of the UK's approach to the commercialisation of emerging technologies through creating early stage critical mass in an area of disruptive technology. SynbiCITE was set up in 2013 with a £28 million commitment over 5 years comprising of grants from Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council (BBSRC), Innovate UK and its industrial and academic partners. SynbiCITE and our partners, across the UK and globally, are committed to developing this technology through responsible innovation, which encompasses ethical, societal and environmental considerations.

Syncona, is a leading FTSE 250 healthcare company focused on creating, building and scaling a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 20- 25 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders. We take a long-term view, underpinned by a strategic capital base which enables us to maintain significant ownership positions in our companies and provides us with control and flexibility over the management of our portfolio. We believe we have the team, track record and skill-set to capture the superior returns available from commercialising exceptional science.

SynGenSys creates product-specific libraries of synthetic genetic parts for next-generation biomedicines and biomanufacturing processes. Our philosophy is simple: all products and production processes are unique. Therefore core genetic assemblies used for therapy or biomanufacturing should harbour custom synthetic DNA parts and circuits designed to be fit for a specific purpose.

Synthace is a digital experiment platform built for high-performance life science R&D teams to help them run more powerful experiments and accelerate scientific progress. It allows biologists to design, plan, and automate experiments in a single place, then automatically gather structured experiment data and metadata in a unified no-code environment.

SyntheticGestalt is an AI startup focused on the life sciences sector, particularly in drug and enzyme discovery. Founded in 2018, the company operates from dual headquarters in London and Tokyo. It utilizes advanced machine learning models to enhance the design, discovery, and analysis of both small and large molecules. The company offers services in drug and enzyme discovery, collaborating with prestigious universities in the UK and Japan. This partnership emphasizes its commitment to scientific research and development in biotechnology. SyntheticGestalt has a diverse international team with expertise in entrepreneurship, pharmaceuticals, consulting, and AI, fostering a supportive work environment that encourages professional growth. With a small team of 11 to 50 employees, SyntheticGestalt is a private limited company incorporated in the UK. Its operations reflect a strong dedication to innovation in the life sciences, supported by grants and collaborations with academic institutions.

Tagomics is a privately held company founded in 2020, with 2-10 employees. It is working to transform disease diagnosis through genetic, epigenetic, and fragmentomic features to identify disease-associated biomarkers and provide insights for disease profiling.

Talisman Therapeutics is a human stem cell drug discovery company, based in Cambridge, UK. We are committed to revolutionising the discovery of treatments for Alzheimer’s disease (AD). Our novel human stem cell models of AD provide a transformative platform for rapid and more therapeutically relevant compound identification, thereby offering the potential to significantly accelerate drug discovery and, more importantly, de-risk subsequent development.

Tata Elxsi is amongst the world's leading providers of design and technology services across industries, including Automotive, Broadcast, Communications, and Healthcare. Tata Elxsi is helping customers reimagine their products and services through design thinking and the application of digital technologies such as IoT (Internet of Things), Cloud, Mobility, Virtual Reality, and Artificial Intelligence. Tata Elxsi is truly home to a billion possibilities. We believe in opportunities for everyone - to be bold, and curious and seek to shape the future. Explore what's possible, discover what you love to do, and find accelerated paths for growth. At Tata Elxsi, you matter.

A new approach to halting the spread of tau pathology and destruction of nerve cells in the brain Precision immunotherapy for the treatment of tau-related frontotemporal dementia (FTD-tau) and progressive supranuclear palsy (PSP)

TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.

T-Cypher Bio is an early-stage, innovative biotechnology company based in Oxford, UK. We believe that TCR-based therapeutics have the potential to transform the treatment of solid tumours, as well as autoimmune & inflammatory conditions. Yet challenges in the identification of therapeutically relevant targets and TCRs has limited the application of such therapies. Our goals: - Develop next generation TCR therapies for treatment of cancer and autoimmune disease - Innovate to make TCR therapies widely available to patients About T-Cypher - Founded in 2021 based on exclusive technology licenses from University of Oxford, and with Oxford Science Enterprises as the major shareholder - Proprietary disease target and TCR discovery platform - Expanding TCR-bank against novel, differentiated targets - Differentiated approach to multiplexing TCRs in therapeutic T-cells - Diverse team with experienced leadership from prominent companies covering cell therapy, gene engineering, immune oncology, autoimmune disease and computational biology

Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately 2 billion people globally. BRIMOCHOL PF has completed its first Phase 3 pivotal trial (BRIO-I) and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and UCL Technology Fund.

Tepnel Pharma Services is a Scottish based FDA and MHRA inspected contract research laboratory. We support pharmaceutical research and development for both small and large molecules with an emphasis on inhalation, oral dosage, parenteral and peptides/proteins. The mission of Tepnel is to Support Drug Development whilst Improving Patient Outcomes. A major aspect of this is helping to address the paradigm of sustainable healthcare economics within a post Brexit, 21st century healthcare system. Our aim as a Scottish owned company is to grow in Scotland, develop our business in Scotland and challenge the perceived ways of working to create a new but compliant way of working that adopts a vested philosophy whereby mutuality of benefit is delivered to our stakeholders around our quality framework that ensures total quality from start to finish.

Founded in 1996 by a group of highly experienced healthcare professionals with a wide range of pharmaceutical industry and academic experience, The Micron Group has grown around this core of expertise, and now has offices in the UK, USA and South Africa. From these locations The Micron Group has global capabilities to deliver full clinical outsourcing , data management, medical communications and consultancy services. While initially an anti-infective specialized organisation, and still an authority in this field, The Micron Group has evolved to posses the expertise required to deliver our full range of services in the fields of respiratory, cardiovascular, neurology, dermatology, endocrinology, rheumatology, and oncology. Regardless of the field or the project, The Micron Group consistently strives to deliver a service that is flexible, preemptive and precise, ensuring projects are delivered on time and on budget, while going above and beyond expectation.

Theolytics is a biotechnology company working to transform innovative therapies that represent the promise of lasting cures. The company harnesses viruses to combat cancer and is focused on developing next-generation oncolytic viral therapies.

TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf's strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company's clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos' neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

We make brand new ingredients on the which the world's biggest consumer product companies are building the healthier, more sustainable and more abundant products of the future. Making system-wide impact means starting from the beginning. We go all the way back to the farmyard, using agriculture's most abundant renewable resource: fiber-rich side streams that don't typically make their way into the food system, like stems, hulls, husks and cobs. We use deep science knowledge and analytics to identify unique opportunities. We then develop the science from manufacturing to application to create completely new and highly scalable solutions to global problems. With our first ingredient, Supplant™ sugars from fiber, your favorite treats can look, feel and taste like they're supposed to. But because it's made from fiber, sugars from fiber is lower in calories, has a low glycemic response compared to glucose, and is prebiotic.

ThirtyFiveBio is an early-stage drug discovery company that was established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of GPR35. We are currently engaged in a fully enabled drug discovery program to identify novel small-molecule modulators of GPR35

STADA Thornton & Ross focuses on a three-pillar strategy consisting of consumer healthcare products, generics, and specialty pharmaceuticals. We’ve been caring for British customers and patients since 1922, and with state-of-the-art manufacturing sites in West Yorkshire and Lancashire, are determined to continue caring for people’s health for generations to come. We are one of UK's leading producers of consumer healthcare products, owning trusted brands such as Covonia, Savlon, Hedrin, Nizoral and Cetraben as well as the cleaning brand Zoflora, which is bought by more than two million households. In keeping with STADA’s global strategy, in the UK we also offer a broad portfolio of branded and generic medicines, across a wide range of therapeutic areas, including dermatology, respiratory, oncology, kidney disease, bone health and many more. With our proven generics and biosimilars, we support a sustainable and cost-efficient NHS, widening patient access to effective treatments. Are you looking for an exciting job opportunity to advance your career in the healthcare industry? Explore our job vacancies: www.thorntonross.com/careers

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®'​) technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care. In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.'​, rebranded 'TRX BioSurgery'​ in February 2018. January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany. In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

Tiziana Life Sciences is a dual-listed* (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases and cancer related to the liver. Our clinical pipeline includes drug assets for Crohn's Disease, COVID-19 and Progressive Multiple Sclerosis and Hepatocellular Carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience. *Note: Our market cap for TLSA is likely not accurate because its shares are listed on both the London Stock Exchange and the NASDAQ.

We are developing cancer treatments that specifically target the cancer stem cell population in tumors. Targeting these cells will prevent relapse and disease progression leading to long-term patient benefit.

Torbay Pharma is a licence holder and global specialist in the manufacture and supply of terminally sterilized injectables for the hospital market. We work with generic pharmaceutical companies seeking to ensure their sterile injectable products get to market reliably and without delay. As a CMO and CDMO, we offer fill/finish services for terminally sterilised injectables into plastic and glass vials and ampoules. Our specialist portfolio includes licensed and unlicensed terminally sterilised injectables, electrolyte solutions for total parenteral nutrition (TPN) compounding and a range of non-sterile oral solutions. Established in the 1970s as part of the Torbay and Devon NHS Foundation Trust, we have grown into a 250-strong team operating from our purpose built manufacturing facility in Paignton, UK. November 2023 saw us receive investment from NorthEdge, we’re now Torbay Pharmaceuticals Ltd. Torbay Pharma offer niche product experience and capabilities, an agile approach and a team of experts who genuinely care. Our determination and flexibility at every step, ensure quality products are efficiently supplied to market, with clear communication and consultancy throughout the process. If you think we can help you with your next project, visit our website: www.torbaypharma.com

TrakCel design, deploy and support digital Cellular Orchestration Solutions that track and manage all the components of the Cell and Gene Therapy supply chain, helping therapy developers to deliver therapies to patients safely and efficiently for both clinical and commercial stage therapies. For each Advance Therapy Patient journey, from sample collection through logistics, manufacturing and final treatment, TrakCel's flagship platform, OCELLOS orchestrates every step, providing a comprehensive chain of custody, chain of identity and traceability throughout. Always remembering there is a patient at the end of everything we do. We innovate. We unite. We transform tomorrow. Want to know more about how TrakCel could transform your therapy supply chain, get in touch and book a free product demo. Join us. See the journey.

tranScrip is a highly specialist pharmaceutical consultancy providing strategic expertise, therapeutic experience and operational excellence across the entire product lifecycle. We build product strategies as well as design and execute development programmes and commercialisation activities. Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts, offer truly flexible bespoke solutions and support to maximise the value of products. We help to expedite the development and commercialisation of products for the benefit of patients worldwide.

Treos Bio is a clinical stage company introducing a disruptive computational technology to change the paradigm of cancer immunotherapy development by resolving the dual challenges of patient and tumor heterogeneity. We use proprietary therapeutic peptides, produced through commercially scalable processes without need for tumor biopsy, to stimulate clinically effective cancer-specific immune responses in patients predicted by our diagnostic tests to respond.

TRIMTECH has a growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs and TRIMGLUEs. The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.

Trio Medicines Ltd (Trio) is a small pharmaceutical company founded in 2005, wholly owned by Hammersmith Medicines Research Ltd (HMR), a CRO. Here, we focus on developing treatments for rare and unmet medical needs with the aim of improving the health and quality of life of patients around the world. Here at Trio, we are currently focused on producing effective treatments through the targeting of G-Protein Coupled Receptors (GPCRs) for a wide range of conditions. Our therapeutic expertise spans inflammatory, respiratory and cardiovascular conditions, as well as gastric neuroendocrine tumours (an orphan disease).

Manufacturing.

Trogenix unites cutting-edge technologies in genomics, oncology, immunotherapy, and gene therapy to create a revolutionary therapeutic approach through its Odysseus platform. Using proven AAV vectors, our proprietary Synthetic Super-Enhancers (SSEs) are delivered directly to tumour cells without detection. Our SSEs enable unprecedented precision in gene control, effectively revealing cancer to the body's immune system and killing tumour cells. For any cells escaping Trogenix's technology, our 'Trojan horse' reawakens the immune system, countering recurrence and offering potentially curative 'one-and-done' treatments for aggressive tumours. With our lead asset showing curative potential in preclinical glioblastoma studies, we're poised to transform treatment paradigms across multiple cancer types and explore applications beyond oncology, such as regenerative medicine.

Tropic Biosciences develops high-performing commercial varieties of tropical crops whichpromote grower well being, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. Some of the products being developed are disease resistant bananas and caffiene-free coffee.

TRX's technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer, CNS and respiratory diseases and diseases of the immune system using a clinically and commercially proven approach.

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science. We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.

At TTP we work with start-ups through to big corporates, across multiple sectors, to solve challenging problems steeped in technology. By combing passion and flexibility with a deep expertise in science, engineering, and design, we help our clients unlock opportunities and make brilliant things happen. We're independent, we're free-thinkers and we're agile to the core, and for over 35 years it's helped us find better solutions faster – time and time again. We take a multidisciplinary approach, and our teams are set up around the project needs, which means we can tackle your problem holistically from the start. What's more, we'll be on your side and work with you as one team, and we'll want the project to succeed as much as you do.

TYG oncology is a biotech company that offers novel cancer immunotherapies based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodulation) technology platform. Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific and controlled immune response against cancer.

Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need. Founded 13 years ago, the Company has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS). As the partner chosen by many leading industry and academic organisations for their drug discovery programmes, Ubiquigent's experience spans the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis. Ubiquigent has an internal pipeline of drug discovery programmes and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-Targeting Chimeras (DUBTACs) for partnering and commercialisation.

Ultromics pioneers precision heart failure detection. Our groundbreaking platform, EchoGo®, is revolutionizing the diagnosis of heart failure using artificial intelligence and cardiac ultrasound. Our technology empowers clinicians to make precise, efficient, and accurate assessments, drawing from the largest known heart disease dataset in echocardiography. We target challenging cardiac diseases, starting with HFpEF, to support timely diagnosis and early intervention. In collaboration with the Mayo Clinic, Johnson & Johnson, and Pfizer, we are continuously developing innovative diagnostic tools aimed at halting the progression of heart failure. Learn more: https://www.ultromics.com/. Follow Ultromics on social media for the latest news, X: https://x.com/ultromics, LinkedIn: https://www.linkedin.com/company/ultromics/.

VacV Biotherapeutics is a cancer immunotherapy company developing innovative viral-based therapies for cancers. Launched in 2022 by cancer immunotherapy pioneers Professor Yaohe Wang, Professor Nicholas Lemoine, Dr. Louisa Chard Dunmall and Dr. Peng Liu, VacV employs a unique approach to immunotherapy based on the Vaccinia virus to stimulate a patient's immune system to fight cancer while simultaneously destroying cancer cells. This approach offers many advantages over existing immunotherapies, including minimized toxicity, higher specificity and efficacy, allowing for efficient systemic delivery of an immunotherapy for the first time.

VaxEquity is a biotechnology company amplifying the impact of RNA vaccines and therapeutics, through using its next generation self-amplifying RNA (saRNA) platform. The Company uses saRNA to provide greatly enhanced protein expression, combining better tolerability with slower release and thermostability. VaxEquity is pioneering a next generation approach by modifying its saRNA to modulate the immune response and thereby overcoming current limitations. The flexibility of the Company’s platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. VaxEquity was founded in 2020 by Professor Robin Shattock, the Head of Immunology of Infection at Imperial College London and is led by a world class team who are pioneers in the field of RNA.

Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork. For further information, please visit Vectura's website at www.vectura.com

Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.

Verona Pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. We are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (COPD) and cystic fibrosis (CF), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. We are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. In addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA and on the London Stock Exchange in the United Kingdom under the ticker symbol VRP.L. We are headquartered in London and have offices in the United States.

Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.

Viramal is a Specialty Pharmaceutical Company developing a portfolio of therapies in the fields of male & female sexual health focussing on the utilisation and application of sex steroid hormones. Viramal’s patent protected technology platform facilitates superior drug delivery both transdermally and to sensitive female reproductive areas with an outstanding safety profile. Similar to cosmetic creams, Viramal’s products have excellent patient acceptability, and unlike competitors does not require alcohol for API solubility or absorption enhancement. All of the Company’s products benefit from the avoidance of the First Hepatic Pass, and the safety/ metabolite concerns that result other marketed products, particularly in Menopausal Hormone Therapy. The portfolio is made up of products in the following area’s: 1. Sex Steroid Hormone Deficiencies * Testosterone Replacement for Men * Menopausal Hormone Therapy 2. Reproductive & Fertility * Fertility Support * Endometriosis & Fibromyomas – treating symptoms and enabling fertility within women of reproductive age 3. Contraception & General Sexual Health * Safer and more patient-acceptable daily & emergency contraceptives * Gynaecological health Viramal’s lead product, TestoCream, is expected to be filed for a New Drug Application to the FDA in the US in 2017/18. TestoCream is a testosterone replacement therapy, similar to a cosmetic cream, applied to the skin. Unlike competing products, TestoCream is neither messy nor watery, requiring a smaller area for application, and it is also quick drying. Testosterone is only soluble in alcohol, with competing products having an alcohol content of around 70% or more. TestoCream offers a far safer alternative, having less than 3.5% alcohol, reducing the risk of skin irritation.

Virax Biolabs is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases.

Virusight has developed an AI-powered digital Healthcare platform that enables affordable, ultra-fast diagnostic testing solutions that provide highly accurate results in less than 20 seconds. SpectraLIT®, Newsight Imaging's miniaturized Spectrophotometer device combined with Virusight's unique AI algorithm, is a revolutionary Digital Healthcare Platform for immediate medical diagnoses. (e.g, Pathogens, Urine Analysis, Early Cancer Biomarkers Detection and more) Virusight Diagnostic is a Joint Venture between Sheba‘s ARC, the medical innovation arm of Sheba Medical Center, Israel's largest hospital and Newsight Imaging, Manufacturer of SpectraLIT®.

WaveBreak (www.WaveBreakTx.com) is a biopharmaceutical company focused transforming drug discovery for neurodegenerative diseases, targeting the fleeting protein intermediates central to many disease pathways that are beyond the reach of conventional drug discovery approaches. WaveBreak has built a unique drug discovery platform to target the transient protein intermediates—the oligomers—in these disease pathways, to interrupt the molecular mechanisms that are the source of oligomer generation with small-molecule therapeutics. WaveBreak is focusing this platform first on some of the greatest unmet medical needs of our time: Parkinson’s disease, Alzheimer’s disease, and ALS. WaveBreak was previously Wren Therapeutics.

We're creating a win-win situation for food producers, consumers and the environment, using innovative technology to transform whole plants, like carob & barley, into deliciously sustainable ingredients. Sourcing from abundance, we're making alternatives that leave a better taste in your mouth. No limits on flavour or innovation, just products that put people, planet and your palate first. Big Chocolate's number one on our list. With more than 1 million child labourers estimated to work in the Ivory Coast & Ghana alone, and more CO2 emissions pound-for-pound than cheese, lamb or chicken, the industry is ripe for change.

Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers. The company has raised significant investment to accelerate biotechnology innovations and has a team of 10 employees.

Xgenera is dedicated to transforming cancer diagnosis through their groundbreaking multi-cancer early detection (MCED) test. With a mission to save lives by identifying cancer at its earliest stages, Xgenera leverages cutting-edge technology and advanced algorithms to detect a wide range of cancers with exceptional accuracy. By detecting cancer earlier, when treatment options are most effective, Xgenera aims to improve patient outcomes and ultimately reduce the global burden of cancer. Backed by data from large patient cohorts and ongoing research, Xgenera's MCED test holds the potential to revolutionise cancer diagnosis around the world. With a commitment to empowering individuals and healthcare providers with timely, actionable information, Xgenera is at the forefront of the fight against cancer, paving the way for a future where early detection saves lives.

Wisdom Sales + Marketing helps small and midsized food companies grow their business. We do this by providing food brokerage services representing food companies in National Retail and Food Service Restaurant Chains Accounts in North America. Many of our customers need more than just sales support to grow as a result we also provide management consulting in the areas of strategic planning, acquisition / divestiture support, ROI marketing analysis, sales and marketing structure and alignment, branding, innovation / product development, advertising, and consumer promotion. If you need help selling or buying a business, or raising capital we may also be able to help.

Yellowstone aims to unlock a new class of therapeutically targetable frequently expressed antigens with potential to significantly transform patient lives. Spun out of the University of Oxford, Yellowstone is built around the pioneering research of Professor Paresh Vyas, a world-renowned scientific academic, key opinion leader and practising clinician with a specialist focus on acute myeloid leukaemia (AML). The Company is headquartered in Oxford, UK, with backing from a leading FTSE 250 healthcare company, Syncona.

Yourgene Health (formerly Premaitha) develops molecular diagnostic products that will have a positive impact on human health and is currently focused in the field of prenatal screening.

YouSeq is a biotechnology company founded in 2018 that specializes in molecular biology product development, particularly in multiplex Next-Generation Sequencing (NGS) and qPCR technologies. The company aims to simplify complex molecular diagnostics for researchers and clinicians, leveraging over 30 years of collective expertise among its founding team. YouSeq is committed to innovation and customer-centric solutions, with a focus on societal impact through charitable initiatives. The company develops user-friendly NGS and qPCR kits for detecting multiple diseases simultaneously, ensuring compatibility with various sequencing platforms. YouSeq also offers specialized multiplex panels and reagents optimized for high-throughput detection. During the COVID-19 pandemic, the company demonstrated its scalability by shipping over 5 million tests globally. YouSeq serves researchers, diagnostic laboratories, and healthcare providers, targeting global markets in infectious disease diagnostics and precision medicine. The company emphasizes a fulfilling work culture and pledges a portion of its profits to charitable causes, including educational support in Uganda.

Zetta provides large-scale genomic data management using distributed database technology and best practice security techniques to leverage genomicdata benefits while preserving data privacy.